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Chapter 1: Introduction 
Targeted Delivery 
Annexin A5 
The unifying element tying together the therapeutics presented in this thesis 
is annexin A5. The protein, annexin 5 (ANXA5), is a membrane management 
protein that specifically binds to apoptotic cells. The natural ligand of ANXA5 
displayed by apoptotic cells is phosphatidylserine. The aminophospholipid 
phosphatidylserine (Ptd-L-Ser) is a universal marker of mammalian cell stress. The 
expression of Ptd-L-Ser is triggered by a diverse range of cellular pathologies, most 
notably cellular trauma, oncogenesis, or infection. Annexin plays several critical 
roles in the pathogenicity of these disease states. Notably, members of the annexin 
family mediate coagulation, enable macrophage-dependent phagocytosis, and 
participate in immune cell activation [1, 2]. During participation in these biological 
processes, ANXA5 binds and recognizes Ptd-L-Ser in a Ca2+-dependent manner [3, 
4]. The unique bow shape of ANXA5, formed by 4 repeating domains of 5 alpha 
helixes each, facilitates the recruitment of calcium and the polymerization of 
ANXA5 trimers (Figure 1) [5].  Our previous work has demonstrated that ANXA5 
derived therapeutics can be targeted to Ptd-L-Ser expression [6-8]. In this thesis I 











The aminophospholipid Ptd-L-Ser is an integral component of the 
eukaryotic plasma membrane. Sharing the hydrophilic phosphate head and twin 
hydrophobic fatty acid tails common to all phospholipids, Ptd-L-Ser can be 
differentiated from its lipid brethren by a single amino acid, serine, which caps the 
phosphate head (Figure 2).  Unlike many phospholipids, the distribution of Ptd-L-
Ser across the plasma membrane is not uniform.  Ptd-L-Ser is sequestered solely to 
the inner leaflet of the plasma membrane of healthy cells by members of the 






cellular pathologies, most notably cellular trauma, oncogenesis\ or infection Ptd-L-
Ser is translocated to the outer leaflet of the plasma membrane. There the 
expression of Ptd-L-Ser serves as a “dead man’s switch”, signaling that the cell is 
dying.  The expression of Ptd-L-Ser on dying cells is recognized by host immune 
elements, triggering cell clearance by phagocytosis [1, 10, 11]. In contrast to its 
normal role as a mediator of the host immune system, Ptd-L-Ser expression is 
hijacked by many diseases to promote disease progression. 
 
Figure 2: Phosphatidylserine (Ptd-L-Ser). 
 
 In cancer, the expression of Ptd-Ser is a necessary part of oncogenesis. All 
lethal tumors share several etiological hallmarks including: uncontrolled 
proliferation, failure of apoptosis, angiogenic activity, evasion of the immune 
system, and metastasis.  One antigen intrinsically tied to each of these hallmarks is 
the membrane phospholipid Ptd-L-Ser. During oncogenesis, Ptd-L-Ser promotes 
uncontrolled proliferation through PI3K/Akt/mTOR activation [12, 13]. 






blocking T-cell mediated apoptosis [14]. Additionally, Ptd-L-Ser expression 
promotes tumor growth by M2 macrophage dependent angiogenesis [15, 16]. In a 
similar manner, Ptd-L-Ser expression suppresses immune recognition of the tumor 
by promoting immunosuppressive phagocytosis [17]. Finally, phosphatidylserine 
promotes metastasis by increasing the fluidity of the cellular membrane [18-20]. 
 In malaria, the expression of Ptd-L-Ser is a hallmark of cellular infection 
[21-23]. When the infected cell is damaged by parasite entry, host cell catabolism, 
and parasite replication, the damaged membrane expresses Ptd-L-Ser [24, 25]. The 
expression of Ptd-L-Ser is not only a byproduct of parasite growth, but an 
intentional survival strategy [9, 22, 26-28]. The expression of Ptd-L-Ser promotes 
parasite survival and disease progression. For instance, infected cells evade 
immune recognition by Ptd-L-Ser dependent-sequestration within the vascular 
endothelium [29, 30]. Furthermore, the increased expression of Ptd-L-Ser signals 
to the host immune system that the cell is undergoing orderly apoptosis, and 
encourages immune suppressing phagocytosis, in effect downregulating the host’s 









Diseases of Interest 
Malaria 
Malaria is the single most deadly infectious disease, infecting 214 million 
individuals a year of which almost 438 thousand will die.  Discounting direct 
mortality, malaria represents a significant burden on the health care system of many 
countries. In malaria endemic countries, malaria accounts for almost one half of all 
hospital visits [32, 33]. Compounding these issues is the spread of drug resistant 
malaria. Emerging strains of the Plasmodium parasite responsible for malaria are 
resistant to all known pharmaceutical treatments [34]. There is a significant need 
for new antimalarial therapeutics.  
Malaria is an infection of the blood characterized by the invasion of host 
erythrocytes by parasites of the Plasmodium genus. The Plasmodium parasite 
undergoes a complex multistage lifecycle within its human host and its mosquito 
vector (Figure 3). In its human host, the parasite primarily infects cells within the 









Figure 3: Lifecycle of the malaria parasite [35].      
 
 
Figure 4: Life stages of the malaria parasite.  Giemsa stained blood slides of P. 
bergei infected BALB/cj mouse blood demonstrating two of the key stages of the 
plasmodium lifecycle. Young, ring-stage parasites (left) appear as small dots within 






The lifecycle stages of the parasite within host erythrocytes are of prime 
clinical significance as this stage is responsible for the manifestation of disease 
symptoms and associated mortality [36, 37]. The parasite replicates solely within 
these host cells.  Upon entry into a host erythrocyte, the Plasmodium parasite begins 
remodeling the cell, using the host cell as camouflage from the immune system, a 
source of food, and an incubator for its rapid replication [38]. Antimalarial drugs 
act on the parasite at this stage, while it is replicating within a host cell.  Commercial 
antimalarial drugs exploit the physiological differences between the parasite and 
healthy cells. The vast majority of drugs interfere with parasite-host cell catabolism 
and inhibit parasite growth [39]. 
 
 Breast Cancer 
Breast cancer is the most commonly diagnosed cancer among women and 
is a leading cause of female mortality. When detected early on, patients have a 94% 
5-year survival rate, which drops to only 10% once metastasis has occurred. In 
breast cancer, one of the most significant challenges with traditional treatment 
modalities is the efficient delivery of chemotherapeutics to the tumor. Less than 
0.7% of the dose reaches the tumor [40, 41]. One promising field of anticancer 






Targeted biologics such as antibody-drug conjugates increase the dose of 
chemotherapeutic reaching the tumor. 
 
  Melanoma 
Skin cancer is the most frequently diagnosed form of cancer. However, excepting 
melanoma, cancers of the skin are responsible for relatively few annual deaths (< 1, 000) 
[42-44]. Despite its infrequent appearance in dermatology, cutaneous malignant melanoma 
(CCM) represents the most frequent source of skin cancer related deaths. When CCM 
metastasizes, patient survival rates fall as low as 5%. Over the last half-decade rapid 
advances in biologic therapeutics have spawned a new generation of treatments, increasing 
patient survival and quality of life. A large body of work has focused on combinatorial 
therapies employing immunostimulation with traditional treatment modalities. 
 
 Lymphoma and leukemia 
Hematological malignancies such as lymphoma and leukemia are unique 
among cancers. Typically originating from host immune cells, these malignancies 
do not form solid tumors, but rather form diffuse “liquid” tumors. Leukemia is the 
presentation of these cancerous cells within the blood. Lymphoma is the 
presentation of these cancerous cells within the lymphatic system. Leukemia can 
be categorized as acute or chronic depending on the time course of progression. 






Hodgkin’s Lymphoma is characterized by the presence of abnormally large B-cells 
called Reed-Sternberg Cells, all other types of lymphoma are classified as Non-




The protein cystathionine-γ-lyase (CGL) is a metabolic enzyme with 
antimicrobial activity. As a key piece of the metabolic sulfur savaging pathway, 
CGL recycles thiol containing metabolites [45]. Additionally, our lab has 
undertaken several point mutations of CGL conferring additional methionine lyase 
activity. In previous work, cystathionine-γ-lyase E58N, R118L, and E338N 
mutations were introduced to impart nonnative methionine γ -lyase activity, 
resulting in broader enzyme substrate reactivity [8]. This mutant cystathionine-γ-
lyase (mCGL) variant has been employed successfully by our lab in enzyme-
prodrug therapy (EPT) along with the methionine analog selenomethionine 
(setmet)[6, 46]. In EPT, the nontoxic prodrug selenomethionine is converted into 








Single-Walled Carbon Nanotubes 
Carbon nanotubes are a promising tool for photothermal tumor therapy due 
to their high stability, large surface area to weight ratio, and high thermal 
conductivity. It has been shown that about 84% of the heat generated by 
radiofrequency excitation within a nanotube is transmitted to its surrounding 
substrate [47-49]. This property of thermal dispersion can be utilized for cancer 
ablative therapies to cause temperature-based homeostatic disruption. Once the 
temperature of a cell rises above 47°C, irreversible cell death by ablation occurs 
which is characterized by cell necrosis and tissue coagulation [50, 51]. Nanotubes 
can be single-walled (SWCNTs) or multi-walled (MWCNTs). For a tumor ablative 
therapy, SWCNTs are preferred over MWCNTs. This electrostatic screening 
diminishes the incident field within the structure. Studies have shown that the 
dominant power dissipation from MWCNTs is due to the outermost shell, which 
results in significantly decreased absorption compared to SWCNTs [52].  
 
Chlorambucil 
Chlorambucil (CMB), is the one of the first successful chemotherapeutic 
drugs ever employed to treat cancer [53, 54]. In modern medicine CMB has 
remained the standard of care for leukemia for almost one century due to its potent 






CMB, is an alkylating agent with significant reactivity to DNA [57-60]. While 
DNA interchelation is the primary mechanism of CMB induced apoptosis, to a 
lesser extent CMB is also capable of alkylating other cellular structures [61]. This 
process is limited by the formation of an aziridinium derivative of chlorambucil, a 
process highly dependent on pH [61, 62]. 
 
Ampicillin 
The beta-lactam penicillin derivative, ampicillin (AMP), was discovered in 
1958 by the addition of a single amino group to a benzylpenicillin [63-65]. In 
contrast to traditional antibiotics such as penicillin, this new therapeutic was active 
against both gram-positive and gram-negative bacteria. The unexpected gram-
negative activity and wide spectrum of antibacterial activity helped to establish 
AMP as the first choice for the treatment of many diseases including S. aureus, E. 
coli, H. influenzae and S. pneumoniae. Most notably, AMP is used to treat 
whooping cough, typhoid fever, and bacterial meningitis. AMP works primarily 
through suicide inhibition of bacterial transpeptidases, where it covalently modifies 








Discovered in 1972, the bidentate, cyclobutene dicarboxylic acid derivative 
of platinum, carboplatin, is the standard of care for treating many forms of cancer 
[66]. Carboplatin is of prime clinical significance due to its remarkably broad 
anticancer activity in multiple forms of cancer. Synthesized from cisplatin, 
carboplatin is well tolerated compared to other platinum agents which can be some 
of the most toxic commercially available chemotherapeutics. Carboplatin’s primary 
mechanism of action is DNA alkylation. Despite its frequent clinical use, 
carboplatin suffers from significant side effects, and only marginal increases in 
prognosis.  
 
Scope of Thesis 
 Bioconjugates are a rapidly growing group of biologically active therapeutics 
employed in many biomedical disciplines. These therapeutics are synthesized by 
conjoining biomolecules with agents such as drugs, toxins, or other biomolecules. 
In much the same way as a complex machine is merely an amalgamation of simple 
parts, bioconjugates are an amalgamation of simple molecules, and the resulting 
products are more than the sum of their parts. Bioconjugates consisting of simple 
molecules can perform novel complex biological functions. This dissertation will 
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Chapter 2: Photothermal Therapy Combined with Checkpoint 
Inhibition in Cancer Treatment 
Abstract 
The selective near-infrared photothermal ablation of EMT-6 tumors with 
annexin A5 (ANXA5) functionalized single-walled carbon nanotubes (SWCNT) 
synergistically enhances an anti-CTLA-4 dependent abscopal response. We 
confirm the selective accumulation of ANXA5-SWCNT in tumor vasculature by 
fluorescent spectroscopy, and the resulting targeted SWCNT-dependent near-
infrared ablation of tumors using thermal imaging.  We then demonstrate the 
synergism between this targeted photothermal ablation modality and 
immunostimulation in several models of invasive metastatic cancer. Notably in the 
orthotopic EMT6 model of breast cancer, we observe a synergistic decrease in 
tumor regrowth and a corresponding increase in survival following the combination 
of SWCNT-ANXA5 targeted photothermal ablation and anti-CTLA-4 checkpoint 
inhibition. We observe an increase in splenocytes of the cytolytic CD8(+) T-cell 
and helper CD4(+) T-cell lineages in mice receiving the combinatorial therapy, may 









Breast cancer is one of the most lethal forms of cancer, especially in woman, 
where it is responsible for more deaths than any other form of cancer. When breast 
cancer metastasizes, patient five-year survival rates fall below 25 percent. Over the 
last half-decade rapid advances in biologic therapeutics and nanotechnology have 
spawned a new generation of treatment options providing a rich opportunity to 
investigate combinatorial therapies. We investigate the combination of selective 
photothermal ablation and checkpoint inhibition in several models of metastatic 
cancer. By employing a recombinant protein-nanotube conjugate, consisting of 
single-walled carbon nanotubes (SWCNTs) and the tumor targeting protein 
annexin A5 (AXNA5) we selectively target tumor tissue for photothermal ablation 
using near-infrared (NIR) laser light.  
Photothermal ablation is the use of light to heat tissue above 60 °C. 
Exposure to high temperatures leads to tissue death via necrosis and can be used as 
an alternative treatment modality for drug resistant tumors. A previous study 
comparing the response of breast cancer to hyperthermia (39 – 45 °C), a slow 
heating of tissue, versus ablation showed that ablation temperatures were able to 
eradicate hyperthermia resistive tumors.  
One promising development in the treatment of tumors by ablation is the 






attention as versatile nanoparticles in diagnostics and therapeutics for drug 
delivery, photodynamic therapy, and NIR contrast enhancement. SWCNTs have an 
intrinsic excitation in the NIR range (700–1100 nm). This excitation heats the 
surrounding tissue inducing cell death via coagulative necrosis, rupturing of cell 
membranes, and denaturing of proteins. The use of NIR ablation with nanotubes is 
further enhanced by the presence of a the “biological window”, where light easily 
penetrates several millimeters into tissue.  
Harnessing the phosphatidylserine (Ptd-L-Ser) ligand, annexin A5 
(ANXA5), we direct a single-walled nanotube-protein conjugate (SWCNT-
ANXA5) to Ptd-L-Ser expressing tumor vasculature. The SWCNT-ANXA5 
conjugate is generated by conjugating ANXA5 to a SWCNT backbone via a 
heterobifunctional DSPEG-PEG-malameide linker (Figure 6).  
 
 











Figure 6: The therapeutic overview of SWCNT photo-ablative therapy. Nanotubes 
introduced to the blood stream accumulate to Ptd-L-Ser expressing tumor cells and 
tumor vasculature by ANXA5 dependent binding.    
 
We develop the resulting ANXA5-SWCNT conjugate as part of a photothermal 
therapeutic modality in vivo in the B16F10 melanoma, 4T1 breast cancer and 
EMT6 breast cancer cell lines.  We further expand on this treatment with the 









While primarily classified as either single-walled (SWCNTs) or multi-
walled (MWCNTs), nanotubes can be further characterized by their diameter. 
Carbon nanotubes can be imagined as sheets of graphene rolled into a tube. Since 
graphene has a stereospecific structure, the angle at which the carbon nanotube is 
rolled determines the diameter of the sheet. Additionally, since the sheet is 
comprised of individual ridged bonds of carbon, the diameter of the tube can only 
decrease or increase by some factor of a carbon bond length and rolling angle [67]. 
The diameter equation uses the chirality values ‘m’ and ‘n’, where ‘n’ and ‘m’ are 
the number of hexagonal units along the graphene sheet in two opposite direction. 
The addition of these vectors represents the imaginary circumference of the carbon 
nanotube. Diameter can be calculated from chirality according to the following 
formula.  
𝑑 = 0.0783 ∗ (𝑛 + 𝑚 + 𝑛𝑚) .  
SWCNTs have diameters ranging from 0.4 to 2 nm, while MWCNTs have 
diameters from 1 to 100 nm with wall thicknesses of 0.2 to 2 nm [68, 69]. 
Nanotubes chirality can be further distinguished based on their chirality into zigzag, 
armchair, and chiral. Zigzag nanotubes occur when m = 0 and the sheet is rolled 
along the n-axis. Armchair nanotubes occur when m = n. Chiral nanotubes such as 






chiral diameter of a carbon nanotube has a huge influence on the nanoparticle’s 
physical properties. For instance, chirality determines if a carbon nanotube is a 
semiconductor or a metal [69]. The 6,5-SWCNTs employed in this study are 
semiconductors. More detailed analysis of the chirality, size, and composition of 
the SWCNT employed in this study can be found in the Appendix D and E.  
 
Materials and Methods 
Materials 
The AXA5 vector was constructed as part of a pET-30 Ek/LIC plasmid 
previously, using Gibson fragment assembly cloning[70]. Bovine serum albumin 
(BSA), Triton X-100, EDTA, β-mercaptoethanol, PMSF, and Tris-acetate-EDTA 
buffer were from Sigma-Aldrich (St Louis, MO). Sodium phosphate and sodium 
dodecyl sulfate (SDS) were from Mallinckrodt Chemicals (Phillipsburg, NJ). 
HPLC grade ethanol was from Acros Organics (Waltham, MA). His-trap columns 
were from GE Healthcare (Chicago, IL). Flow cytometry staining buffer, 
fixation/permeabilization buffer, permeabilization buffer, and Slide-A-Lyzer 
dialysis cassettes (3.5 kDa) were from Thermo Fisher Scientific (Waltham, MA). 
The 2 and 100 kDa dialysis membranes were from Spectrum Laboratories (Rancho 
Dominguez, CA). Roswell Park Memorial Institute cell medium (RPMI-1640) and 






serum (FBS) was from Atlanta Biologicals (Lawrenceville, GA). Tryptone, yeast 
extract, and kanamycin monosulfate were obtained from Alfa Aesar (Ward Hill, 
MA). Sodium hydroxide, potassium chloride, and sodium chloride were from VWR 
Inc (Radnor, PA). HRV-C3 protease was from Sino biologics (Portland, OR). All 
antibodies were obtained from Biolegend (San Diego, Ca. Single-walled carbon 
nanotubes (SWCNT) were obtained from CHASM (Boston, MA).  
 
Cell Lines and Cell Culture 
Drug resistant, triple-negative 4T1 breast cancer cells were transfected with 
tdTomato (Td) by Krais et al. as previously described [42]. B16F10 melanoma and 
4T1-Td breast cancer cells from ATCC (Manassas, VA) were cultured in Roswell 
Park Memorial Institute (RPMI-1640) medium supplemented with 10 % fetal 
bovine serum (FBS) and 1% penicillin/streptomycin antibiotics (100 U mL-1 and 
100 μg/mL-1 respectively).  EMT6 breast cancer cells from ATCC (Manassas, VA) 
were cultured in Waymouth’s MB 752/1 medium with 2 mM L-glutamine 
supplemented with 15% fetal bovine serume (FBS). All cells were grown at 37 ° C 
and 100% humidity under 5 % CO2. All cells were passaged using 0.25 % (w/v) 








The SWCNT-ANXA5 conjugate was prepared as previously described 
[70]. In brief, SWCNTs were solubilized in 1% sodium dodecyl sulfate (SDS) by 
repeated cycles of sonication and centrifugation. SWCNTs were then 
functionalized with a heterobifunctional 1,2-distearoyl-sn-glycero–3–
phosphoethanolamine–N- maleimide (polyethylene glycol) (DSPE-PEG-MAL) 
linker. The sulfur reactive heterobifunctional linker was then capped with the 
protein annexin A5 (ANXA5).  An in depth nanotube conjugation protocol can be 
found in Appendix C.  
 
 
Mouse Tumor models  
B16F10 melanoma, 4T breast cancer, and EMT6 breast cancer tumor 
models were employed in this study. C57/bl6 and Balb/cj mice were obtained from 
JAX (Frenchman Bay, ME). Primary tumors were induced by an orthotopic 
injection of 106 cells in the case of EMT6 and 4T1 tumors, and by a s.c. flank 
injection of 106 cells in the B16F10 model. The B16F10 tumor model furthermore 
required artificial induction of pulmonary metastasis by i.v. inoculation of 106 cells 
[71]. All other models spontaneously metastasized. Tumor model setup and 








Immunophenotypic antibodies and cytometric analysis was conducted as 
described previously [72]. A detailed protocol of sample preparation and staining 
can be found in Appendix C.  
 
NIR Irradiation 
Mice were irradiated 3 hours post treatment with SWCNT-ANXA5 with a 
diodeVET-50 NIR (980 nm) laser at an energy and power level of 175 J/cm2 and 
1 W/cm2 respectively for 175 seconds. The NIR beam was set to irradiate an area 
5 mm outside the tumor.   
 
IR Temperature Analysis 
Temperature was monitored in mice receiving NIR irradiation using a 
handheld FLIR TG165 Spot Thermal Camera from Raymarine ITC (Fareham, 
UK) set to auto scan for maximum detected temperature.  
 
Therapeutic Antibodies 
In the B16F10 model antibodies and immunomodulators were first given 48 






was give twice weekly. Nucleotidase depleting anti-CD-73 (clone: TY/23; 5 
mg/kg) was given twice weekly. The immunomodulatory drug cyclophosphamide 
(50 mg/kg) was given weekly. In the EMT6 model of breast cancer anti-CTLA-4 
(clone: 9H10; 100 µg) was given twice per week. 
 
Ex Vivo SCWNT Detection 
 Single-walled carbon nanotubes were detected in ex vivo tissue samples 
using a NS3 nanospectralyzer from Applied NanoFluorescence (Houston, TX). 
Standards can be found in Appendix D: Characterization of SWCNT. 
 
Statistical Analysis 
Data was analyzed with Graphpad Prism software. Statistical significance 
was assessed using a one-way ANOVA and Tukey-Kramer multiple comparisons 
test. Statistical significance of survival curves was determined by the Mantel-
Haenszel log-rank test. Multiple comparisons were corrected by the Bonferroni 
threshold. Unless otherwise listed, all samples were n = 5 not including outliers as 
determined by the Tietjen-Moore test.  Error is represented graphically as standard 
error unless error did not exceed the size of the plotted mean point symbol, in which 








Results and Discussion 
SWCNT Dose-Dependent Ablation 
Increasing doses of SWCNT-ANXA5 enhance targeted photothermal 
ablation of B16F10 tumors (Figure 8). C57BL6/j B6 albino mice were inoculated 
with B16F10 cells on day zero and tumor size was monitored until a size of 5 mm 
in diameter was reached. Mice were then given SWCNT-ANXA5 conjugate by i.v. 
injection and irradiated 3 hours later. Tumor volumes were then monitored twice 
weekly. Increasing doses of SWCNT-ANXA5 increased the efficacy of targeted 
photothermal ablation. After photothermal therapy, the tumor was undetectable at 
doses of 0.8 mg/kg. However, tumor regrowth occurred at all doses of SWCNT-
ANXA5.  







Figure 7: Dose-dependent tumor regrowth. C57/BL6 albino mice were inoculated 
with 106 B16F10 melanoma cells and tumors were allowed to reach 5 mm in 
diameter. Tumor volumes were recorded for 2 weeks in B6 albino mice following 
targeted ablation at varying doses of SWCNT-ANXA5. On day 0, mice received 
varying i.v. doses of SWCNT-ANXA5, and 3 hours later the tumors were 
stimulated with NIR irradiation at an energy and power density of 175 J/cm2 and 1 
W/cm2, respectively (t = 175 s).  Data is presented as mean ± SE (n = 7).    
Following unsuccessful eradication of tumors in the B16F10 model at low 
doses of ANXA5-SWCNT, a repeat experiment was performed in the 4T1 model 
of breast cancer, employing higher doses of ANXA5-SWCNT. BALB/cj mice were 
given an orthotopic inoculation of 105 4T1 cells, and tumor growth was monitored 
twice weekly. When tumors reached a diameter of 5 mm, mice received various 
doses of SWCNT-ANXA5, and the primary tumor was irradiated as previously 
described (Figure 9). At doses of SWCNT-ANXA5 greater than 0.8 mg/kg, 
complete tumor eradication was observed. At doses of 1.2 mg/kg SWCNT-ANXA5 


































no tumor regrowth was observed. Moving forward, we choose the lowest dose 




Figure 8: The growth of primary tumors following SWCNT-NIR photoablation as 
a function of SWCNT dose. Tumor volumes were recorded for 7 weeks in BALBcj 
albino mice following targeted ablation at varying doses of SWCNT-ANXA5. 
Cancer cells were inoculated on Day 0. On day 15, mice received varying i.v. doses 
of SWCNT-ANXA5, and 3 hours later the tumors were stimulated with NIR 
irradiation at an energy and power density of 175 J/cm2 and 1 W/cm2, respectively 
(t = 175 s).  Data is presented as mean ± SE (n = 5).    
 
Thermal Kinetics 
Having determined that a dose of 1.2 mg/kg SWCNT-ANXA5 was 






photothermal ablation (Figure 10). BALB/cj mice bearing EMT6 tumors of at least 
5 mm in diameter were given a dose of 1.2 mg/kg SWCNT-ANXA5. Three hours 
after the administration of SWCNT-ANXA5 tumors were irradiated as described 
previously. During irradiation, tumor temperature was recorded with an infrared 
FLIR thermal imager. Mice who received a dose of 1.2 mg/kg SWCNT-ANXA5 
prior to irradiation (right) had significantly high temperature profiles within the 
tumor then control mice (left). Over the period of irradiation, the maximum 
temperature reached temperatures as high as 60 ºC (Figure 11).  This temperature 










Figure 9: Temperature profile of the tumor and surroundings of mice after 
phothermal therapy. B16F10 tumors ( d = 5 mm) were irradiated (175 J/cm2 and 1 
W/cm2; d = 15 mm) and the temperature was recorded using a handheld infrared 
imager for mice receiving a saline control dose (left), and mice which received a 









Figure 10: Mice bearing EMT6 tumors were irradiated and the max temperature of 
the tumor was recorded. Balb/cj mice bearing EMT6 tumors of at least 5 mm in 
diameter were injected by i.v. with 1.2 mg/kg SWCNT-ANXA5. Three hours later 
tumors were irradiated with a NIR laser at an energy and power density of 175 
J/cm2 and 1 W/cm2, respectively (t = 175 s).  The temperature of tumors from mice 
receiving SWCNT was singnificantly higher then controls at t = 175 s (P ≤ 0.005)  
Data is presented as mean ± SE (n = 3).    
At the conclusion of irradiation for mice which received SWCNT, the 
average max tumor temperature was 54.7 ° C, this temperature was sufficient to 
ablate the tumor [50]. The temperature of tumors in the saline control group 
remained below 40 °C, a temperature which provides minimal therapeutic benefit 
[73-75]. In the SWCNT-ANXA5 treated group, visible ablation of the tumor was 
characterized by the rapid discoloration of the tumor. Following discoloration of 
the tumor the skin began to tighten taking on a shriveled appearance. Within 48, 
hours a significant eschar formed at the site of photothermal ablation. Complete 
skin regrowth took several weeks. (Figure 12).  































Figure 11: Photothermal therapy combining SWCNT-ANXA5 and NIR irradiation 
lead to the complete tumor regression as seen 2 weeks following treatment. A 
representative s.c.  melanoma tumor before (left) and 3 weeks after (right) targeted 
laser stimulation in conjunction with a SWCNT-AV dose of 1.2 mg/kg. Tumors 
had a diameter of d = 4.6 ± 0.2 (mean ± SE) mm.   
Biodistribution 
Following the successful identification of a dose of SWCNT-ANXA5 
capable of permanent tumor eradication, we undertook a biodistribution assay 
(Figure 13). Balb/cj mice (n = 5) were treated with 1.2 mg/kg SWCNT-ANXA5 
and at select times mice were euthanized for tissue collection. Samples were 
prepared as described previously [76]. Samples were first compared on the basis of 
the percent injected dose detected in each organ. We observed the majority of 
SWCNT-ANXA5 accumulation primarily in the liver, heart, spleen, kidneys, tumor 






accumulation within the tumor as well. Trace amounts of SWCNT-ANXA5 were 
detected in the brain, large intestines and small intestines.  
 
Figure 12: Biodistribution of SWCNT-ANXA5. Following an i.v. injection of 1.2 
mg/kg SWCNT-ANXA5 in BALB/cj mice, tissue was excised at 1,2,3 and 4 
months after inoculation, and SWCNTs were detected in the liver, spleen, kidneys 
and lungs. Trace amounts of SWCNTs (<1% I.D) were detected in the heart, brain, 
and small intestine. Data is presented as the mean ± SE (n = 3). 
 
It is important to note that the biodistribution of SWCNT on the basis of 
%ID, does not correlate well with the absolute concentration of SWCNT within a 
target tissue. This is primarily due to the differences between organ weights. For 
instance a given % ID within an organ will correspond to a higher  concentration 
within smaller organs, and smaller concentrations within larger organs.  Comparing 






within the kidney, followed closely by the liver and spleen (Figure 1 4). High 
concentrations of SWCNT can be detected in the heart, lungs and kidneys as well. 
Trace amounts of SWCNT were detected in the brain and intestines.  
 
Figure 13: Biodistribution of SWCNT-ANXA5. The SWCNT-ANXA5 conjugate 
was i.v. injected in Balb/cj mice as at a dose of 1.2 mg/kg, and the concentration of 
SWCNT was then measured at 3 hours in the tumor. The SWCNT concentration 
was measured in various organs of mice without tumors after 1, 2, 3 and 4 months 
(left to right). Data is shown as mean ± SE (n = 3). 
 
Abscopal Effect 
Enhanced survival and reduced tumor growth was observed in mice 
receiving a combination of SWCNT-ANXA5 directed photothermal therapy and 






and treated as described in Figure 15. Photothermal therapy exceled at destroying 
orthotopic EMT6 primary tumors but failed to enhance survival overall survival. 
Immunostimulation with α-CTLA-4 enhanced overall survival but failed to 
eradicate primary tumors. The synergistic combination of SWCNT-ANXA5 
directed photothermal therapy and α-CTLA-4 immunostimulation enhanced 
survival, leading to 55 % survival.  
 
Figure 14: EMT6 breast cancer model timeline. Mice received an s.c. inoculation 
of 106 EMT6 metastatic breast cancer cells on day 1, and then received checkpoint 
inhibiting anti-CTLA-CTLA-4 antibodies on days 8,11, and 16. Tumors were 
irradiated on day 12 with SWCNT-ANXA5.   
As early as the 1950s, researchers observed that localized tumor irradiation 
had a significant effect on distant tumors [77]. Mechanistic studies have established 
that the systemic nature of the abscopal effect is due to the host’s immune response 






a growing body of work demonstrates that photothermal therapy can induce an 
abscopal effect as well. Numerous studies have demonstrated that thermal ablation 
in combination with the checkpoint inhibitor anti-CTLA-4, produces a heightened 
immune response [82-88]. We observe an abscopal response following 








Figure 15: The growth of primary tumors and the survival of mice bearing EMT6 
tumors. Mice with well developed orthotopic syngeneic tumors (d ≥ 5 mm) were 
administered an intravenous systemic dose of 1.2 mg/kg SWCNT-ANXA5. 
Tumors were then irradiated (arrow) with mild laser light using a Diodevet-50 NIR 
system for 175 s, at a power density of 1 W/cm2 on dat 12 (arrow). Anti-CTLA-4 
was injected on days 8, 11, and 16 (100 µg per injection). Photothermal therapy 
eradicated primary tumors, and the combination of photothermal therapy and 
immune checkpoint inhibition significantly increased survival compared to controls 
(P ≤ 0.05). Data is shown as time since tumor inoculation, with tumor volume 









Using flow cytometry, we examined the relative populations of immune 
effector cells in mice (Figure 16, Figure 17, Figure 18). Mice were inoculated with 
EMT6 and treated as described earlier. Two weeks after treatment mice were 
sacrificed and we identified both the percentage and relative count of multiple types 







Figure 16: Splenocyte cell populations in mice treated by various treatments. The 
relative counts and % composition of neutrophils and MDSC monocytic 
splenocytes was examined 14 days following photothermal treatment. Data is 



















































































































































































Figure 17: Splenocyte cell populations in mice treated by various treatment 
(continued). The relative counts and % composition of Fox3p and macrophage 
splenocytes was examined 14 days following photothermal treatment. Data is 





























































































































































Figure 18: Splenocyte cell populations in mice treated by various treatment 
(continued). The relative counts and % composition of Helper T cells and Cytotoxic 
T cells was examined 14 days following photothermal treatment. Data is presented 
























































































































































In mice receiving both anti-CTLA-4 checkpoint inhibition and SWCNT-
ANXA5 targeted photothermal therapy, we observed immunophenotypic changes 
in splenocyte populations. Specifically, we observed increases in both tumor killing 
CD4(+) T-helper cells and CD8(+) cytolytic cells (Figure 20).  
 
 
Figure 19: Photothermal therapy in conjunction with α-CTLA-4 checkpoint 
inhibition significantly increased the number of CD4(+) and CD8(+) splenocytes. 
For the three groups treatment was the same as previously described. Data is for 
cells in the spleen at 2 weeks following treatments and is presented as the mean ± 
SE (n = 3). Significance is indicated by *** (P ≤ 0.005).   
Increases in CD4(+) and CD8(+) cell counts correlated to increases in 
spleen sizes observed during necropsy. Increased spleen size indicates a heightened 
immune response. The spleen is comprised of multiple cell types, the most common 
of which are of the CD4(+), CD8(+), and B-cell lineages [89, 90]. While not 
explored in this body of work, we would expect B-cell counts to increase along 






T-cells, assist in humoral immunity by facilitating other immune cells by cytokine 
stimulation and direct cell-cell interactions. Cytolytic T-cells, also known as 
CD8(+) cells, directly kill tumor cells. Increases in CD4(+) and CD8(+) cell counts 
are indicative of a systemic abscopal immune response.  
 
Conclusion 
The aminophospholipid Ptd-L-Ser is actively sequestered to the inner leaflet 
of the plasma membrane of health cells. In a tumor, this tightly regulated Ptd-L-Ser 
membrane asymmetry breaks down and Ptd-L-Ser is expressed on the outer leaflet 
of cancerous cells and the vascular endothelium. The presence of Ptd-L-Ser solely 
within the tumor serves as a tumor specific antigen which can be used in targeted 
therapeutics. We employ the natural ligand of Ptd-L-Ser, ANXA5, in a protein-
nanoparticle conjugate to sensitize tumors to photothermal ablation. The 
combination of ANXA5 directed SWCNT dependent photothermal ablation with 
anti-CTLA-4 checkpoint inhibition significantly increased survival in the orthoptic 
EMT6 model of breast cancer.   
We observe SWCNT-ANXA5 dependent near-infrared ablation of tumors 
using thermal imaging and confirm the selective accumulation of ANXA5-SWCNT 
in tumor vasculature by fluorescent spectroscopy. We further establish the 






the synergism between this targeted photothermal ablation modality and 
immunostimulation in several models of invasive metastatic cancer. Notably in the 
orthotopic EMT6 model of breast cancer, we observe a synergistic decrease in 
tumor regrowth and a corresponding increase in survival following the combination 
of SWCNT-ANXA5 targeted photothermal ablation and anti-CTLA-4 checkpoint 
inhibition. We observe an increase in splenocytes of the cytolytic CD8(+) T-cell 
and helper CD4(+) T-cell subsets in mice receiving the combinatorial therapy. The 
increase in tumor suppressing T-cells would lead to enhanced tumor rejection and 







Chapter 3: Antimalarial Activity of  Chimeric Fusion Protein 
Abstract 
A cytocidal mutant enzyme, cystathionine- γ-lyase (mCGL), was targeted 
to phosphatidylserine (Ptd-L-Ser) expressed on malaria infected erythrocytes 
through fusion with the protein annexin A5 (ANXA5). The resulting fusion protein 
selectively accumulates to Ptd-L-Ser expressing parasite infected erythrocytes by 
ANXA5-dependent binding, where the enzyme catalyzes the generation of toxic 
products. The enzymatic activity of parasite localized mCGL was highly toxic to 
infected erythrocytes, but minimally toxic to healthy erythrocytes. We demonstrate 
the antimalarial activity of this fusion protein both in vitro and in vivo. 
Introduction 
Malaria is the single most deadly infectious disease, infecting 214 million 
individuals a year of which almost 438 thousand will die.  Discounting direct 
mortality, malaria represents a significant burden on the health care system of many 
countries [32, 33]. In malaria endemic countries, malaria accounts for almost one 
half of all hospital visits. Compounding these issues is the spread of drug resistant 
malaria. Emerging strains of the Plasmodium parasite responsible for malaria are 
resistant to all known pharmaceutical treatments. There is a significant need for 









Using multiple in vitro models and a murine model of the disease, we 
demonstrate the antimalarial activity of the fusion protein ANXA5-mCGL. A 
succinct summary of the therapeutic mechanism of action can be seen below 
(21Figure 20: Therapeutic design philosophy.).  
 
 
Figure 20: Therapeutic design philosophy.  
 
Antimalarial Action 
The antimalarial activity of the fusion protein begins with ANXA5 dependent 
binding to the infected erythrocyte. Once bound to the parasite-infected 






catabolizes multiple thiol-containing compounds such as methionine. This lyase 
activity has a twofold impact on parasite growth and survival. First, many of the 
substrates for mCGl are essential parasite nutrients [92, 93]. The Plasmodium 
parasite lacks many of the common eukaryotic metabolic pathways necessary to 
synthesize these crucial metabolites. Lacking these compounds, the parasite is 
unable to fuel its rabid growth.  Secondly, the byproducts of mCGL lyase activity 
are potent cell toxins. The enzyme mCGL produces byproducts such as hydrogen 
sulfide, reactive oxygen species (ROS), and ammonium. The twofold antimalarial 
action of the enzyme mCGL is further compounded by the parasitic nature of the 
malaria parasite. The parasite actively imports many of the substrates of mCGL to 
fuel its growth [92].  The result of this active transport is an increase in substrate 
concentration susceptible to mCGL activity, further enhancing the therapeutic 
effect of the fusion protein.  
 
In contrast to typical chemotherapeutic agents, ANXA5-mCGL does not inhibit 
parasite growth. The fusion protein selectively targets infected cells for destruction 
by enzymatic action (Figure 22).  Here we present the in vitro antimalarial action 
of ANXA5-mCGL in the P. Yoelii and P. berghei models. Furthermore, we 
demonstrate the in vivo antimalarial action of the fusion protein in the P. berghi 















Figure 21:The antimalarial mechanism of action of the fusion protein mCGL-ANXA5. 





Materials and Methods 
Materials 
An AXA5-mCGL vector was previously constructed as part of a pET-30 
Ek/LIC plasmid using Gibson fragment assembly cloning [46]. Modified giemsa 
stain, bovine serum albumin (BSA), pyridoxal-3-phosphate, Triton X-100, EDTA, 
selenomethionine, and Tris-acetate-EDTA buffer were from Sigma-Aldrich (St 
Louis, MO). His-trap columns were from GE Healthcare (Chicago, IL). Sodium 
phosphate and sodium dodecyl sulfate (SDS) were from Mallinckrodt Chemicals 
(Phillipsburg, NJ). Antifade reagent Fluoro-gel, borate buffer, Hoescht stain, FITC, 
Deep Red Plasma Membrane stain, DAPI, propidium iodide, flow cytometry 
staining buffer, fixation/permeabilization buffer, permeabilization buffer, and LAL 
chromogenic endotoxin quantitation kit were from Thermo Fisher Scientific 
(Waltham, MA). The 2 and 100 kDa dialysis membranes were from Spectrum 
Laboratories (Rancho Dominguez, CA). Roswell Park Memorial Institute cell 
medium (RPMI-1640) and Hank’s balanced salt solution (HBSS) were from ATCC 
(Manassas, VA). Fetal bovine serum (FBS) was from Atlanta Biologicals 
(Lawrenceville, GA). 
 





Cell Lines and Cell Culture 
Murine blood samples infected with Plasmodium yoelii (substrain yoelii; 4-
20 % parasitemia) and wildtype Plasmodium berghei (substrain ANKA; 3-5% 
parasitemia) were kindly donated from the lab of Dr. Noah Butler (OUHSC). 
Plasmodium berghei samples (Substrain ANKA; mutation 507m6c11) were 
obtained through the Biodefense and Emerging Infections Center of the CDC 
(BEI). The P. berghei ANKA mutation 507m6c11 parasites are transformed by 
double cross-over integration using the pL0023 (BEI MRA-792) vector to 
constitutively express green fluorescent protein [94]. In flow cytometric 
applications 507m6c11 parasites are GFP(+).  For in vitro work, samples were 
collected from infected mice and immediately diluted in ice cold RPMI-1640 
supplemented with 10% FBS without antibiotic/antimycotic. Parasites were 
cultured for up to 24 hours at 37 °C and 100% relative humidity using the candle 
jar method [95]. Parasites were maintained for in vivo studies by serial passage in 
mice. Frozen aliquots of P. berghei were stored in medium supplemented with 5% 
DMSO under liquid nitrogen. Cryogenic lots were first passaged in mice twice 
before use during in vivo studies.  
  





Fusion Protein Production 
Recombinant mCGL-ANXA5 was produced and isolated by His-tag 
chromatography, and activity was confirmed by a chromatographic assay as 
previously described [46]. The experimental procedure is given in Appendix A. The 
experimental procedure is provided in Appendix A. Purity was confirmed by SDS-
PAGE. Samples were confirmed endotoxin free by limulus amoebocyte lysate 
assay.  
 
Parasite Models and Cytotoxicity 
In cytotoxicity studies, P. yoelii infected erythrocytes were analyzed by 
flow cytometry. Samples were first gated to select a population of CD71(+) 
erythroid cells [CD71(+) erythrocytes are Ter-119(+)]. Following selection of 
erythrocytes, samples were gated to remove the presence of CD45(+) nucleated 
leukocytes. Nonviable nucleated cells were identified by staining with the cell 
impermeable nuclear stain propidium iodide (PI). The cell impermeable PI stain is 
only capable of staining nucleated cells with compromised cellular membranes 
PI(+). Nonviable parasites were identified after treatment with fusion protein as 
CD45(-)CD71(+)PI(+) erythrocytes. Viability of parasite samples was measured 
following overnight (12 h) or after a short term (3 h) incubation at 37°C using the 





candle jar method. A brief description of the candle jar method can be found in 
Appendix A.  
Fusion protein (mCGL-ANXA5) dependent parasite death was further 
confirmed by both giemsa stain and histological light microscopy examination. 
Fresh samples of infected blood were in incubated for 3 hours with 100 nM fusion 
protein to allow fusion protein binding to parasite surface. Following this brief 
incubation, the samples were washed to remove excess protein and incubated 
overnight with various concentrations of the prodrug selenomethionine (setmet). 
Following treatment, samples were fixed and examined by both giemsa stain and 
differential interference contrast microscopy.  
In a second model of malaria, the viability of fusion protein (mCGL-
ANXA5) treated P. Berghei infected erythrocytes was measured using flow 
cytometry. Samples of infected erythrocytes were gated to remove the presence of 
CD45(+) nucleated leukocytes. The leukocyte free population of cells was then 
gated on recombinant P. berghei parasites. Parasites of substrain ANKA, mutation 
507m6c11 are transformed to be green fluorescent by GFP(+) parasites. Nonviable 
nucleated cells were identified by staining with the cell impermeable nuclear stain 
propidium iodide (PI). The cell impermeable PI stain is only capable of staining 
nucleated cells with compromised cellular membranes PI(+). Nonviable CD45(-) 
GFP(+)PI(+) parasites were quantified and compared to viable CD45(-)GFP(+) 





PI(-) parasite control samples after a short-term (3 h) incubation. 
 
Erythrocyte Damage 
The structure of fusion protein (mCGL-ANXA5) treated P. Berghei infected 
erythrocytes was assessed using flow cytometry. Erythrocytes were identified in 
blood samples as CD45(-)CD71(+) cells. Erythrocyte structure was analyzed by 
flow cytometric FSC/SSC gating. Damaged cells were crudely identified as events 
that deviated from original size gating parameters of healthy erythrocytes. Treated 




The survival of P. berghei inoculated mice was monitored for a period of 
one month. Male CF-1 mice of 6 weeks of age sourced from Charles River (Boston, 
MA) were inoculated with 1 x 106 P. berghei infected erythrocytes by i.p. injection. 
Infected mice were treated the following day with 15 mg/kg fusion protein in 150 
μL of phosphate buffered saline or with phosphate buffered saline control. After 
the all control animals perished, the study was concluded (28 days) and surviving 
treated mice were necropsied. 
 






The weight of mice receiving daily fusion protein (mCGL-ANXA5) or 
saline control treatments was monitored over one month. Male outbred Swiss CF-
1 mice of 6 weeks of age were treated daily with 15 mg/kg of fusion protein by i.p. 
injection for 20 days. Following treatment mice were monitored for 4 weeks to 
observe any changes in weight of behavior.  
 
Flow Cytometry 
Samples of infected blood (100 μL) were harvested in sodium citrate coated 
syringes and immediately diluted with 5 mL of ice cold media. Cell numbers were 
then enumerated using a hemocytometer. Samples (100 μL) were diluted to a final 
concentration of 10 x 106 iRBC per mL-1 with flow cytometry buffer. Samples (500 
μL) were stained with a combination of 0.2 μg of APC α-CD45 (Rat IgG2b, κ; 
clone 30-F11), 0.2 μg of PE α-CD71 (Rat IgG2a, κ; clone R17217), and 5.0 μg of 
propidium iodide (PI). Samples of iRBC were incubated with the antibody cocktail 
for 1 h at 4 °C, protected from light. Cells were then washed (x3) by pelleting (5 
min; 500 g) discarding the supernatant and suspending in 1 mL of flow cytometry 
staining buffer. Following the last wash, cells were suspended in flow cytometry 
staining buffer with PI. Samples were then incubated at 4 °C for 15 minutes in the 
dark. Samples were then analyzed via a BD Accuri C6 flow cytometet (San Jose 





Ca). Detailed flow cytometry gating schema can be found in Appendix A: 
Antimalarial Fusion Protein. 
 
Histology 
Thin blood smears were created on glass microscopy slides from samples 
(15 μL) of iRBC. The smear was allowed to dry for 2 h, and then fixed for 20 s with 
ice cold methanol. Fixed smears were then stained for 45 min with a solution of 
0.02 w/v% modified giemsa stain diluted in deionized water. Samples were allowed 
to dry and then analyzed with a E800 Nikon fluorescent microscope. Pictures were 
captured with a Sony CMOS IMX183 AMscope camera. 
 
Statistical Analysis 
Data was analyzed with Graphpad Prism software. Statistical significance 
of parasite cytotoxicity was assessed using a one-way ANOVA and Tukey-Kramer 
multiple comparisons test. Statistical significance of survival curves was 
determined by the Mantel-Haenszel log-rank test. Multiple comparisons were 
corrected by the Bonferroni threshold. Unless otherwise listed all samples were n 
= 5 not including outliers as determined by the Tietjen-Moore test.  Error is 
represented graphically as standard error unless error did not exceed the size of the 
plotted mean point symbol, in which case the bars were excluded for clarity.  





Results and Discussion 
Plasmodium Yoelii Model 
The P. yoelii model of infection is a murine model of human malaria [96]. 
This model is highly prized by researchers for three reasons. First, the infection is 
nonfatal; animals can be studied after experimental treatment. Second, the yoelii 
strain of plasmodium expands rapidly in the blood (40% parasitemia), providing a 
large pool of parasites for in vitro studies. Finally, the significant P. yoelii - P. 
falciparum homology makes yoelii one of the first choices for in vitro drug testing 
[97]. Here we demonstrate that the fusion protein ANXA5-mCGL has significant 
antimalarial activity as assayed in the P. yoelii model by fluorescent light 
microscopy, flow cytometry and histological staining. 
Using fluorescent microscopy, we assayed fluorescent fusion protein 
accumulation to P. Yoelii infected erythrocytes (parasitemia 40 %) (Figure 23). 
Immediate fluorescent microscopy of the samples revealed accumulation of FITC-
ANXC5-mCGL (green) to parasitized cells (blue). Following this confirmation of 
fusion protein binding, we undertook an initial assay of fusion protein antimalarial 
activity. When cultured overnight with fusion protein, the number of identifiable 
Hoechst stained parasites decreased (Figure 24).  We conclude from this light 





 microscopy data that the fusion protein has ANXA5 dependent 
accumulation and cytotoxicity.  We proceeded to establish the full dose-response 
model of the fusion protein in the P. yoelii model of infection. 
 
Figure 22: Fusion protein binding. Infected erythrocytes (1 x 106) were incubated 
briefly with 0.02 µg/mL of FITC labeled fusion protein (FITC-ANXA5-mCGL) 
and 0.01 µg/mL Hoechst stain. Infected erythrocytes were then washed and 
suspended in HBSS. Fluorescent light microscopy of P. berghei infected 
erythrocyte cultures revealed the accumulation of ptd-L-ser binding annexin-FITC 
(green) on parasitized cells (blue).   






Figure 23: DNA stain of treated and untreated parasites. Erythrocytes infected with 
P.berghei were cultured overnight with a saline control (left) or with 40 nM fusion 
protein (right). The number of Hoechst stained parasites (blue) were significantly 
decreased after treatment with fusion protein.  
The dose-response model of ANXA5-mCGL and P. yoelii was constructed 
by experimental flow cytometry (Figure 25). The viability of parasite samples (n = 
3) was measured following overnight (12 h) incubation at 37°C using the candle jar 
method. Treated samples of infected erythrocytes were gated to select a population 
of CD71(+) erythroid cells. Following selection of erythroid cells, samples were 
gated to remove the presence of CD45(+) nucleated leukocytes. The remaining 
nonviable nucleated cells were identified by staining with the cell impermeable 
nuclear stain propidium iodidie (PI). The 50% cytotoxic concentration (CC50) was 
determined to be 40 nM.  






Figure 24: P. Yoelii treated with Fusion Protein. Samples of infected erythrocytes 
were gated to select a population of CD71(+) erythroid cells (CD71(+) erythrocytes 
are Ter-119(+)). Following selection of erythrocytes, samples were gated to remove 
the presence of CD45(+) nucleated leukocytes. Nonviable parasites within infected 
erythrocytes were identified by staining with the cell impermeable nuclear stain 
propidium iodide (PI). The cell impermeable PI stain is only capable of staining 
nucleated cells with compromised cellular membranes PI(+). Nonviable parasites 
were identified after treatment with fusion protein as CD45(-
)CD71(+)PI(+)erythrocytes. Viability of parasite samples was measured following 
overnight (12 h) incubation at 37°C using the candle jar method. Data is presented 
as the mean ± SE (n = 3).  
The dose-response model of ANXA5-mCGL and P. yoelii was constructed 
using propidium iodide and cytometric analysis. Propidium iodide possesses a 
positive charge and is unable to cross intact cellular membranes [98]. Damaged 
cells such as those in the late stages of cell death have damaged membranes. 





Propidium iodide accumulates in dying cells where it binds to DNA. We observed 
a dose-dependent increase in the propidium iodide fluorescence of parasites when 
treated with ANXA5-mCGL starting at concentrations as low as 30 nM (Figure 25).  
The death of parasitized cells and corresponding increase in propidium iodide 
fluorescence rapidly increased with the concentration of ANXA5-mCGL. The 
concentration of enzyme cytotoxic to half of all parasites (CC50) was 40 nM.  All 
parasites were killed by a concentration of only 50 nM.  
While we observed antimalarial activity solely with the addition of the 
fusion protein, previous work indicated that fusion protein dependent antimalarial 
activity could be increased with the addition of a supplemental substrate of mCGL 
enzymatic activity [8]. Specifically, we hypothesized that the use of the prodrug 
selenomethionine (setmet) would enhance antimalarial mCGL enzymatic activity. 
In an in vitro study employing P. yoelii infected erythrocytes, we found that the 
nontoxic amino acid, setmet, increases the cytotoxic action of the fusion protein 
(Figure 26). While the natural products of mCGL are relatively nontoxic 
compounds such as ammonia and α-ketobutrate, the products of the nontoxic 
prodrug setmet are highly toxic seleno-radical oxygen species (ROS). The number 
of parasites within samples were enumerated by microscopy following enzyme-
prodrug treatment (Figure 27). Samples of infected blood were incubated briefly 
with the fusion protein. Following this incubation , the samples were washed to 





remove excess protein and incubated overnight with setmet. We observed that 
increasing concentrations of setmet decreased the number of observable parasites 












Figure 25: Selenomethionine and parasite viability. The parasite burden of fusion 
protein (mCGL-ANXA5) treated P. Yoelii infected erythrocyte samples was 
determined by giemsa stain and histological light microscopy examination. 
Samples of infected blood were incubated for 3 hours with 100 nM fusion protein 
to allow binding to parasite surface. Following this brief incubation, the samples 
were washed to remove excess protein and incubated overnight with various 
concentrations of the prodrug selenomethionine (setmet). The number of parasites 
per field of view (FOV) were then enumerated. Data is shown as the mean ± SE (n 









Using light microscopy of giemsa stained blood smears, we quantified the 
number of intact P. Yoelii parasites as a function of setmet dose (Figure 26). The 
addition of a supplemental substrate of mCGL enzymatic activity, (setmet), 
increased the antimalarial activity of the fusion protein ANXA5-mCGL in vitro. 
Setmet on its own had no significant effect on the number of parasites observable 
in cell culture. However, starting at concentrations of 10 µM we observed a 
decrease in the number of parasites as the dose of setmet was increased to 1 mM.  
The reported antimalarial activity of selenium derivatives such as selenite and 
methylselenocysteine is several orders of magnitude less than the activity of setmet 
in conjunction with ANXA5-mCGL [99, 100]. Furthermore, much previous work 
examining the antimalarial activity of selenium derivatives has focused on toxic 
oxides such as selenius acid or sodium selenite. The selenium derivative used in 
this study, setmet, is an essential amino acid naturally present in the body. Setmet 
is significantly less toxic than many of these species.   
 
 






Figure 26: Antimalarial action of fusion protein. Giemsa stained blood slides of 
uninfected (left) blood following fusion protein treatment and infected (right) 
untreated erythrocytes. Erythrocytes weakly accumulate giemsa (blue-pink). 
Parasites within the erythrocyte strongly accumulate giemsa (purple-black). 
Parasites were quantified by light microscopy.  
 
 
Plasmodium Berghei Model 
In addition to preliminary work with the P. yoelii strain, the antimalarial 
activity of the fusion protein ANXA5-mCGL was also confirmed in the P. berghei 
model of infection. P. berghei infected erythrocyte viability was measured using 
flow cytometry. The fusion protein was found to have significant antimalarial 
activity in the P. berghei model with CC50 concentrations of 150 and 35 nM after 
3 h and 12 h incubations respectively. 
 






Figure 27: Antimalarial action of fusion protein. The viability of fusion protein 
(mCGL-ANXA5) treated P. Berghei infected erythrocytes was measured using 
flow cytometry. Samples of infected erythrocytes were gated to remove the 
presence of CD45(+) nucleated leukocytes. The leukocyte free population of cells 
was then gated on recombinant GFP(+) parasites. Nonviable parasites within 
infected erythrocytes were identified by staining with the cell impermeable nuclear 
stain propidium iodidie (PI). The cell impermeable PI stain is only capable of 
staining nucleated cells with compromised cellular membranes PI(+). Nonviable 
CD45(-)GFP(+)PI(+) parasites were quantified and compared to viable CD45(-
)GFP(+)PI(-)parasite control samples after a short-term (3 h) incubation with the 
fusion protein at 37°C under 5% CO2 supplemented atmosphere. Data is shown as 
the mean ± SE (n = 3).   
 
 






Figure 28: Antimalarial activity of fusion protein. The viability of fusion protein 
(mCGL-ANXA5) treated P. Berghei infected erythrocytes was measured using 
flow cytometry. Samples of infected erythrocytes were gated to remove the 
presence of CD45(+) nucleated leukocytes. The leukocyte free population of cells 
was then gated on recombinant GFP(+) parasites. Nonviable parasizited 
erythrocytes were identified by staining with the cell impermeable nuclear stain 
propidium iodidie (PI). The cell impermeable PI stain is only capable of staining 
nucleated cells with compromised cellular membranes PI(+). Nonviable CD45(-
)GFP(+)PI(+) parasites were quantified and compared to viable CD45(-
)GFP(+)PI(-)parasite control samples after an overnight incubation (12 h) with 
fusion protein using the candle jar method of parasite culture. Data is shown as the 
mean ± SE (n = 3).  
 
 
The antimalarial activity of the fusion protein was examined in two-time 
course studies. In a short-term study of 3 hours, and a longer study of 12 hours, the 
CC50 concentrations of ANXA5-mCGL were established in the P. berghei model. 
In the 12-hour cytotoxicity experiment, we confirmed the antimalarial activity we 





observed in the P. yoelii model. We observed a similar cytotoxicity profile in the 
P. berghei model, with cytotoxicity starting at 30 nM. Half of all parasites were 
nonviable at a concentration of 35 nM, and all parasites were apoptotic at a 
concentration of 40 nM. The similarity between the cytotoxicity profiles in the P. 
yoelii model and the P. berghei is surprising. The P. berghei model is invariably 
fatal, whereas the P. yoelii model is nonfatal, and typically responds better to 
chemotherapeutics. In the 3-hour study we observed parasite toxicity starting at a 
dose of 50 nM, a CC50 of 150 nM, and no viable parasites were detected at 
concentrations higher than 250 nM. The observed CC50 of 150 nM is startling.  
Traditional chemotherapeutics are poisons whose antimalarial effects are measured 
as the parasite completes multiple lifecycles, and is measured over period of days 
[101]. A brief examination of the literature demonstrates typical cytotoxicity 
experiments lasting 48 hours [102-104]. Whereas typicaly chemotherapeutics take 
several days to kill parasites, the fusion protein ANXA5-mCGL destroys parasites 
in a time frame of only 3 hours. Furthermore, the antimalarial activity of the fusion 
protein exceeds that of traditional chemotherapeutics such as chloroquine (CC50: 









Erythrocyte Damage Index 
During initial antimalarial dose-curve experiments with the P. berghei 
model, we observed dose-dependent damage to erythrocytes (Figure 30).  Samples 
of P berghei infected blood were incubated overnight with fusion protein.  
Following incubation, samples were fixed, stained with giemsa stain, and examined 
by DIC light microscopy. Untreated controls (left) maintained their structure. 
Therapeutic concentrations of fusion protein (100 nM; center) did not alter 
membrane morphology. Excess fusion protein (10 μM) lead to membrane damage 
and the production of cell debris. Concerned with the possibility of nontarget 
destruction of erythrocytes, we evaluated fusion protein dose-dependent 










Figure 29: DIC analysis of erythrocyte damage. The fusion protein (mCGL-
ANXA5) can damage infected erythrocytes. Untreated infected erythrocytes 
(untreated; left) maintain their structure. Therapeutic concentrations of fusion 
protein (100 nM; center) did not alter membrane morphology. A 100-fold increase 
in fusion protein (10 μM; right) lead to membrane damage and the production of 
cell debris.  
Flow cytometry analysis revealed dose-dependent cell structure changes 
(Appendix A: Erythrocyte Damage Flow Scheme). Erythroid cells were identified 
in blood samples as CD45(-)CD71(+) cells, and cell morphology was analyzed by 
FSC/SSC size gating. Damaged cells were identified grossly as events whose 
structure deviated from control erythrocyte samples.  Following an overnight 
incubation, we observed a clear relationship between fusion protein dose and cell 
forward scatter in treated samples. Increasing concentrations of fusion protein 
clearly decreased cell Forward SCatter (FSC). FSC is a measure of cell surface area. 
Decreases in FSC reflect a decrease in cell size.  Increasing doses of fusion protein 
shrink erythrocytes in a manner similar to apoptosis. Following this observation, an 





erythrocyte damage index was defined as the % of structurally damaged cells 
(Figure 31). Following a short-term (left) or overnight (right) incubation, we 
observed an increase in cellular debris, and a corresponding decrease in gated 
erythrocytes.  While dose-dependent changes in cell morphology were observed, 
we note that therapeutic, antimalarial concentrations of fusion protein did not affect 
cell morphology in vitro. Cell damage was only observed at concentrations in 









Figure 30: Fusion protein dependent erythrocyte damage. The structure of fusion protein (mCGL-ANXA5) treated P. 
Berghei infected erythrocytes was assessed using flow cytometry. Erythrocytes were identified in blood samples as 
CD45(-)CD71(+) cells. Erythrocyte structure was analyzed by flow cytometric FSC/SSC gating. Damaged cells were 
identified grossly as events that deviated from original gating parameters of healthy erythrocytes. Treated cell samples 
were analyzed following short-term (left; 3 h) or overnight (right; 12 h) incubation with fusion protein. Increases in fusion 
protein concentration generated an increase in cellular debris, and a corresponding decrease in gated erythrocytes. Data 
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The fusion protein is capable of damaging CD71(+) erythroid cells as 
measured by size analysis. In a 3-hour study we observed the onset of size 
morphology changes in some cells at a dose of 45 nM, significant morphology 
changes in half of all cells at 50 nM (effect concentration EC50: 50 nM), and the 
complete loss of structural normality in all cells at a dose of 60 nM. In a 12-hour 
study, we observed size morphology changes starting at 100 nM, an EC50 of 200 
nM, and the complete loss of structural normality in all cells at a dose of 200 nM.  
While we observed an ANXA5-mCGL dose-dependent change in cell morphology, 
it is important to note that therapeutic concentrations of the fusion protein are less 
than the concentrations where erythrocyte damage was observed.  
We confirmed the difference between dose-dependent antimalarial and 
eryptotic action of the fusion protein by histology (Figure 32). Erythrocytes 
infected with P. berghei were cultured overnight with 50 nM (left) or 100 nM of 
fusion protein (right). Comparative analysis of giemsa stained slides revealed that 
50 nM of fusion protein destroyed infected trophozoites releasing the immature 
parasites (purple). Erythrocytes maintain normal physiologic appearance at 
concentrations as high as 50 nM of fusion protein. In contrast, at concentrations of 









Figure 31: Comparison of fusion protein dose. Erythrocytes infected with P. 
berghei were cultured overnight (12 hours) with 50 nM (left) or 100 nM of fusion 
protein (right). Giemsa stained slides revealed that 50 nM of fusion protein 
destroyed many infected trophozoites releasing the immature parasites (purple). 
Erythrocytes maintain normal physiologic appearance at this dose. In contrast, 
cultures of infected blood treated with 100 nM of fusion protein featured few intact 
cells and abundant cell debris.     
   
Erythrocyte Chemical Damage 
Damage to erythrocytes can be measured using multiple methods; one 
method is the use of spectroscopy to ascertain oxidative damage to hemoglobin. As 
the chemical unit responsible for carrying oxygen within the erythrocyte, chemical 
damage to hemoglobin directly impacts the function of the erythrocyte.  The use of 
many antimalarial chemotherapeutics, especially quinine derivatives, has been 
reported to induce chemical damage to hemoglobin [104, 106]. Oxidative chemical 
damage to hemoglobin, produces derivatives such as methemoglobin and 
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concentrations (~2%), increasing concentrations of these derivatives impair the 
oxygen carrying capacity of erythrocytes [107]. The derivatives of hemoglobin, 
sulfohemoglobin and methemoglobin, have unique spectroscopic signatures. 
Nonfunctional deoxyhemoglobin derivatives, methemoglobin and 
sulfohemoglobin have maxima absorption at 660 nm in relation to hemoglobin 
[108, 109]. The relative oxidation state of drug-damaged hemoglobin was 
determined after 3 h in infected blood by comparative analysis of absorption at 940 
and 660 nm  (Appendix A: Hemoglobin Oxidation).  
Similar to other antimalarial chemotherapeutics, the products of fusion 
protein antimalarial activity can damage hemoglobin. Dose-dependent oxidation of 
blood was first observed visually (Figure 33). Untreated blood (left) rapidly 
acquired a rust brown color when incubated in the presence of excess (10 µM) 
fusion protein. This color change indicates oxidation of erythrocyte hemoglobin 
from a Fe2+ to Fe3+ oxidation state. Enzymatic products of mCGL-ANXA5 include 
radical oxygen species (ROS) capable of oxidizing blood [110-112].  Using 
comparative spectroscopic analysis at 940 and 660 nm, we assayed chemical 
damage to samples of erythrocyte hemoglobin as a log function of fusion protein 
concentration (Figure 34). The fusion protein did not chemically damage 








Figure 32: Oxidation of infected blood by mCGL-ANXA5. Blood infected with P. 
berghei was treated with 10 mM fusion protein for 3 h (right) and compared to 
untreated controls (left). The brown color of the blood incubated with fusion protein 
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Figure 33: Chemical damage of hemoglobin.  Chemical damage of hemoglobin as 
a function of the concentration of fusion protein was measured as the ratio of 
absorbances at 990 to that of 660 after 3 hours. The absorbance of blood at 660 and 
940 nm corresponds to functional hemoglobin and nonfunctional hemoglobin 
respectively. Functional hemoglobin carries oxygen (oxyhemoglobin). 
Nonfunctional hemoglobin derivatives (methemoglobin and sulfohemoglobin) are 
unable to carry oxygen. Quantifying these two hemoglobin states, the health of 
erythrocytes was expressed as the fraction of nonfunctional hemoglobin as a 
function of fusion protein (mCGL-ANXA5) concentration. Data is presented from 
single points).  
We observed ANXA5-mCGL dose-dependent changes in the oxidation 
state of blood as measured by absorbance spectroscopy. We observed oxidative 
damage to the hemoglobin of intact erythrocytes starting at a concentration of 30 
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concentration of 0.8 µM. Oxidation of hemoglobin occurred at concentrations much 
higher than those where cell morphology changes were observed, suggesting that 
the dose limiting factor in ANXA5-mCGL treatment is physical damage to the 
erythrocyte and not chemical damage to hemoglobin.   
 
In vivo Model 
Having both demonstrated the antimalarial activity of the fusion protein in 
two strains of plasmodium and confirmed the safety of the fusion protein by 
chemical, histological and cytometric analysis, we proceeded to ascertain the in 
vivo antimalarial activity of the fusion protein in a P. berghei model. The survival 
of P. berghei inoculated mice was monitored for a period of one month (Figure 35). 
All control mice and 50% of treated mice perished within 11 days. At the 
conclusion of the study (28 days), surviving treated mice were necropsied and 
confirmed to be parasite free. With half of all mice treated with a single dose were 









Figure 34: Survival of P. berghei infected mice. The survival of P. berghei 
inoculated mice was monitored for a period of one month. Male CF-1 mice of 6 
weeks of age were inoculated with 106 P. berghei infected erythrocytes. Infected 
mice were treated the following day with 15 mg/kg fusion protein in 150 μL of 
dPBS or with a saline control. All control mice and 50% of treated mice perished 
within 11 days. At the conclusion of the study (28 days), surviving treated mice 
were necropsied and confirmed to be parasite free. Data represents the survival of 
n = 10 mice.   
In addition to observing survival after a single dose, the safety of the fusion 
protein was confirmed by monitoring mice following daily injections for one 
month. Weight and behavior were monitored for the presence of adverse side 
effects. See Figure 36 for weight changes over time. No changes in behavior or 
weight were observed in mice treated with fusion protein. The rigorous dosing 
schedule (once per day) as opposed to the experimental treatment schedule (once) 








Figure 35: Mouse weight following repeated treatment with fusion protein. The 
weight of mice receiving daily fusion protein (mCGL-ANXA5) or saline control 
treatments was monitored over one month. Male outbred swiss CF-1 mice of 6 
weeks of age were treated daily with 15 mg/kg of fusion protein for 20 days. 
Following treatment mice were monitored for 4 weeks to observe any changes in 
weight of behavior. No changes in behavior or weight were observed in mice 









There is critical need for new antimalarial drugs. Drug resistant strains of 
plasmodium, immune to all known pharmaceutic agents, are sweeping across 
multiple continents endangering billions of people. Here we demonstrate the 
antimalarial activity of a novel chimeric fusion protein. Comprised of a parasite 
targeting domain (ANXA5) and a microcidal enzyme (mCGL), the fusion protein 
specifically binds and destroys parasite infected erythrocytes. The unique 
mechanism of antimalarial activity, targeting a host marker of cell stress (Ptd-L-
Ser), was proven effective in two in vitro models of infection. 
In initial experiments we explored the antimalarial activity of the fusion 
protein in a P. yoelii model of infection. First, we confirmed the localization of 
fusion protein to infected erythrocytes using fluorescent microscopy. We observed 
fusion protein accumulation to infected erythrocytes, increasing the effective 
concentration of the microcidal fusion protein. We then determined the cytotoxic 
antimalarial activity of the fusion protein (CC50: 40 nM) in a 12 h viability assay. 
Finally, we demonstrated the synergism of the fusion protein with a prodrug 
(setmet). Selenium derivatives have demonstrated antimalarial activity, and the 
synergistic activity of the fusion protein with the prodrug setmet could be a possible 
second line treatment [99]. Furthermore, using the fatal P. berghei stain we 






(CC50: 35 nM). Interestingly, in short-term tests (12 h) we still observed 
antimalarial activity, highlighting the rapid antimalarial action of the fusion protein. 
Further work in vivo with P. berghei demonstrated a significant cure rate with a 
single dose. Additionally, repeated daily treatments for 20 days failed to illicit 




















Chapter 45: A Novel Cytostatic Protein-Drug Conjugate 
Consisting of Annexin A5 and Chlorambucil 
Abstract 
Here we present a novel cytocidal bioconjugate (ANXA5-CMB) comprised 
of the protein annexin A5 (ANXA5) and the alkylating agent chlorambucil (CMB). 
The protein component, ANXA5, serves as a vehicle specifically targeting 
chlorambucil to tumor cells. The antineoplastic activity of the mustard derivative 
CMB is enhanced by ANXA5 dependent tumor targeting delivery. We demonstrate 
the synthesis and analysis of this novel ANXA5-CMB conjugate. Furthermore, we 
establish the anticancer activity of the conjugate in vitro using four cell lines, and 
in vivo with two murine tumor models.  
 
Introduction 
Chlorambucil(CMB) was linked to annexin A5 (ANXA5) using 1-Ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS). 
CMB is unique among FDA approved chemotherapeutics. It is the only 
chemotherapeutic with a single carboxylic group and no primary amine groups 
(Figure 36). By selectively activating the carboxylic group of CMB and then 
quenching EDC-NHS chemistry before the addition of ANXA5, it is possible to 






crosslinking products (Figure 37). In typical bioconjugation schema employing 
other chemotherapeutics, side reactions such as protein-protein and drug-drug 
crosslinking produce undesired biproducts, reducing yield. Additionally, the 
cytocidal functional groups of CMB are the bis(2-chloroethyl)amino arms [58]. 
Linking chlorambucil by the carboxylic group does not impact cytocidal activity; 
in fact the bioconjugate was up to 100-fold more cytotoxic than free CMB.  
 
Figure 36: Chlorambucil chemical structure, and linking moiety (circle). The 
nitrogen mustard chlorambucil (MW: 304.2 Da) is unique among FDA approved 
cancer drugs. It is the only antineoplastic agent with a single carboxylic functional 







Figure 37: Chemical Synthesis of CBM-EDC and then CBM-NHS. The NHS derivative (1) was the conjugated to 
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Materials and Methods 
Materials 
An AXA5 vector was previously constructed as part of a pET-30 Ek/LIC 
plasmid using Gibson fragment assembly cloning [46]. Bovine serum albumin 
(BSA), Alamar Blue reagent, Triton X-100, EDTA, TPCK, EDC, NHS, β-
mercaptoethanol, PMSF, and Tris-acetate-EDTA buffer were from Sigma-Aldrich 
(St Louis, MO). His-trap columns were from GE Healthcare (Chicago, IL).  Sodium 
phosphate, and sodium dodecyl sulfate (SDS) were from Mallinckrodt Chemicals 
(Phillipsburg, NJ). Chlorambucil was from TCI America (Portland, OR). HPLC 
grade ethanol was from Acros Organics (Waltham, MA). Antifade reagent Fluoro-
gel, borate buffer, HOIESCHT stain, FITC, Alexa-488, Deep Red Plasma 
Membrane stain, DAPI, Propidium Iodide, flow cytometry staining buffer, 
fixation/permeabilization buffer, permeabilization buffer, and Slide-A-Lyzer 
dialysis cassettes (3.5 kDa) were from Thermo Fisher Scientific (Waltham, MA). 
The 2 and 100 kDa dialysis membranes were from Spectrum Laboratories (Rancho 
Dominguez, CA). Roswell Park Memorial Institute cell medium (RPMI-1640), 
Weymouth’s MB 753/10 medium, and Hank’s balanced salt solution were from 
ATCC (Manassas, VA). Fetal bovine serum (FBS) was from Atlanta Biologicals 
(Lawrenceville, GA). Tryptone, yeast extract, and kanamycin monosulfate were 
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chloride, and sodium chloride were from VWR inc (Radnor, PA). HRV-C3 
protease was from Sino biologics (Wayne, PA). 
 
EDC/NHS Coupling 
Chlorambucil (CMB) was linked to the protein annexin A5 (ANXA5) by a 
zero-length carbodiimide linker (Figure 37) . Insoluble at neutral pH, 10 mg of 
chlorambucil was initially dissolved in 15 µL of an acidic solution of 12 M HCl .  
This solution of chlorambucil salt was then immediately diluted 200-fold in 30 mM 
phosphate buffer.  Using 10 mg/mL 1-ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC), the carboxylic group of 
chlorambucil was modified with an unstable O-acylisourea intermediate. This 
intermediate was then stabilized with the addition of 7 mg/mL N-
hydroxysulfosuccinimide (sulfo-NHS). The reactants were vigorously vortexed for 
15 minutes to facilitate sulfo-NHS-CMB conjugation. The EDC/NHS crosslinking 
reaction was then quenched with 2 µL/mL of β-mercaptoethanol. If EDC/NHS is 
not quenched, carboxylic groups such as those on aspartate and glutamate on 
ANXA5 may be activated in following steps, leading to protein-protein 
crosslinking (Figure 38).  
The synthesized sulfo-NHS-CMB derivative reacts readily with the primary 
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chlorambucil was linked to annexin A5 by incubating 2.5 mL of 1 mg/mL annexin 
in 30 mM phosphate buffer with 1 mL of the sulfo-NHS-CMB derivative. The pH 
of the solution was then immediately titrated to 7.4. The sulfo-NHS-CMB 
derivative and annexin A5 were then gently mixed for 12 hours. Following 
conjugation, the solution was centrifuged for 10 minutes at 12000 g to remove 
precipitates. The resulting supernatant was dialyzed against 2 L of 30 mM 
phosphate buffer for 8 hours. The dialysate was then filtered through a 0.22 µm 
filter and stored at 4 °C for 48 hours protocol is given in Appendix B.  
Protein yields were calculated by Bradford assay.  
 
Figure 38: Possible locations of EDC/NHS crosslinking in ANXA5. Aspartate 
(blue) and glutamate (yellow) carboxylic moieties within the amino acid sequence 
of ANXA5 are possible locations of protein-protein crosslinking.   
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Figure 39: Lysine (yellow) residues with a primary amine. The lysine residues 
within ANXA5 are a possible location of protein-protein crosslinking in EC/NHS 
chemistry and the target of CMB modification.  
 
Quantification of Chlorambucil 
 The concentration of chlorambucil can be determined by the synthesis and 
quantification of a photocatalyzed chlorambucil derivative. Standards of 
chlorambucil were solubilized in an acidic solution of 12 M HCl acid and diluted 
200-fold in a solution of 30 mM phosphate buffer and 10% DMSO. Samples were 
then incubated in a UV RMR-500 photochemical reactor for 1 hour. The UV-
catalyzed cyclic addition of DMSO to chlorambucil generates a perhydrothiazocine 
derivative (Figure 40).  
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Figure 40: Synthesis of perhydrothiazocine. The perhydrothiazocine derivate is 
fluorescent (358/434; ex/em). Fluorescence was measured on a microtiter plate 
reader (360/460; ex/em) and found to be proportional to concentration.  
 
Cell Lines and Cell Culture 
Drug resistant, triple-negative 4T1 breast cancer cells from ATCC 
(Manassas, VA) were transfected with tdTomato (Td) previously [6]. 4T1-Td breast 
cancer cells were cultured in Roswell Park Memorial Institute (RPMI-1640) 
medium supplemented with 10 % FBS and 1% penicillin/streptomycin antibiotics 
(100 U mL-1 and 100 μg/mL-1 respectively). EMT6 breast cancer cells were 
cultured in Waymouth’s MB 752/1 medium supplemented with 2 mM L-glutamine 
and 15% FBS. Nonadherent L1210 lymphocytic leukemia and P388 lymphoblastic 
lymphoma cells were cultured in Dulbecco’s modified eagle’s medium (DMEM) 
with supplemental glucose enriched with 10 % FBS, and 1% 
penicillin/streptomycin antibiotics (100 U mL-1 and 100 μg/mL-1 respectively). All 
adherent cells were passaged using 0.25 % (w/v) Trypsin in 0.53 mM EDTA.  All 








In vitro Cytotoxicity studies 
Cells (5000 cells/well) were seeded and cultured for 48 hours in 96 well 
microtiter plates. Cells were then incubated with chlorambucil or the protein 
conjugate for 24 hours. Following incubation cell viability was assayed by 
AlamarBlue assay as previously described [46].  
 
Mouse Tumor models  
All procedures were conducted under protocols approved by the 
Institutional Animal Care and Use Committee (IACUC) of the University of 
Oklahoma. Two strains of mice were employed to assay two different types of 
cancer. The first strain was female BALB/cj mice from JAX (Frenchman Bay, ME) 
at six weeks of age. These mice were used in conjunction with the breast cancer 
cell lines 4T1 and EMT6. The second strain employed was male DBA mice from 
Charles River (Lebanon, CT) of six weeks of age. These mice were used in 
conjunction with the lymphoblastic leukemia, P388 and L1210, cell lines. In breast 
cancer studies, mice were injected s.c. in the 4th mammary fat pad with 5 x 104 4T1 
or EMT6 mammary carcinoma cells in a 100 μl suspension of saline on day 0. 
Tumor volumes were recorded twice weekly to ascertain progression of the disease. 
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leukemia studies mice received an i.p. inoculation with 106 L1210 or P388 
lymphoblastic leukemia cells in a 100 µL suspension of saline on day 0. Leukemia 
progression was monitored by survival and necropsy. Mice received doses of 10 μg 
of chlorambucil as part of a free salt or as part of a protein – drug conjugate. The 
annexin A5 – chlorambucil conjugate was administered daily for the duration of 
the study.  
Statistical Analysis 
Data was analyzed with Graphpad Prism software. Statistical significance 
of parasite cytotoxicity was assessed using a one-way ANOVA and Tukey-Kramer 
multiple comparisons test. Statistical significance of survival curves was 
determined by the Gehan-Breslow-Wilcoxon test and Mantel-Haenszel log-rank 
test. Multiple comparisons were corrected by the Bonferroni threshold. Samples 
were n = 5 unless otherwise listed, outliers as dertermined by the Tietjen-Moore 
tests were no included in the sample numbers. Error is represented graphically as 
standard error unless error did not exceed the size of the plotted mean point symbol 
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Results and Discussion 
Synthesis of ANXA5-CMB 
Synthesis of an ANXA5-CMB conjugate was confirmed using SDS-gel 
electrophoresis (Figure 41). Three samples were run between two protein ladders. 
ANXA5 (left; MW:36 kda) and two separate batches of ANXA5-CMB conjugate 
(center and right; MW:40 kDa) demonstrate the increase in molecular weight as 
chlorambucil (MW:0.302 kDa) is covalently attached to the annexin A5. Molecular 
weights of the band above and the band below the samples are 53 and 35 kDA 
respectively. We observed an increase in MW of approximately 3 kDA following 









Figure 41: Molecular weight of ANXA5 (left) and ANXA5-CMB (right). 
Synthesis of a chlorambucil – annexin A5 conjugate was confirmed using SDS-gel 
electrophoresis. Three samples were run between two ladders. Annexin A5 (left; 
MW:36 kDa) and two batches of chlorambucil - annexin A5 conjugate (center and 
right; MW:40 kDa) demonstrate the increase in molecular weight as chlorambucil 
(MW:0.302 kDa) is covalently attached to the annexin A5. Molecular weights of 
the band above and the band below the samples are 53 and 35 kDA respectively  
 
The EDC/NHS linking chemistry does not contribute the molecular weight 
of the ANXA5-CMB construct. Any increase in molecular weight is the result of 
CMB addition to ANXA5. Therefore, the molecular weight of the resulting 
ANXA5-CMB conjugate can only increase by a factor of CMB’s molecular weight. 
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increase in ANXA5 molecular weight from 36 kDa to about 40 kDa. This increase 
of about 4 kDa corresponds to the addition of 13 CMB to each annexin. 
Furthermore, we observe no smearing of the protein bands in the ANXA5-CMB 
groups. Band smearing is indicative of the formation of side products such as 
ANXA5-ANXA5 polymers during the synthesis of ANXA5-CMB. Band smearing 
would also indicate CMB heterofunctionalization of ANXA5 producing ANXA5-
CMB derivatives of various molecular weights.  In two different batches of 
ANXA5-CMB we observe a sizable change in molecular weight, and the 
production of a relatively pure product.  
The extent of CMB addition to ANXA5 was also confirmed by fluorescent 
assay. The ANXA5-CMB conjugate samples were incubated under UV-light with 
5 % DMSO to generate a fluorescent derivative of CMB. The formation of the 
fluorescent derivative, perhydrothiazocine, by photocatalyzed cyclic addition of 
DMSO allowed the quantification of CMB on ANXA5 (Figure 42). Using this 
method we determined a molar ratio of typically 8-12 CMB per ANXA5. This 
corresponded to roughly a mass value of 10% CMB (m/m %) in the ANXA5-CMB 








Figure 42: Log[CMB]-perhydrothiazocine fluorescence quantification. An 
unknown concentration of chlorambucil can be determined with fluorescent 
spectroscopy. When chlorambucil is in the presence of DMSO, UV light catalyzes 
the production of fluorescent perhydrothiazocine (358/434; ex/em). The excitation 
and emission of perhydrothiazocine was measured (360/460; ex/em) and found to 
be proportional to concentration. Samples depicted as mean ± SE (n = 3).   
 
ANXA5-CMB Binding 
The accumulation of ANXA5-CMB in tumor cells was first demonstrated 
in B-cell derived lymphocytic L1210 cells using an ANXA5-fluorescein 
isothiocyanate (FITC) derivative. ANXA5 was functionalized with FITC, a 
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imaging of L1210 cells incubated with ANXA5-FITC demonstrated the 
accumulation of ANXA5-FITC (green) to Deep Red Plasma Membrane stained 
L1210 (red) cells (Figure 43).  
 
 
Figure 43: FITC-ANXA5 (green) indicates the presence of ANXA5 on the 
membrane of L1210 cells statined with Deep Red Plasma Membrane Stain (red).  
 
The accumulation of ANXA5-CMB was also indirectly confirmed by 
fluorescent analysis of perhydrothiazocine formation. The UV catalyzed 
heterocyclic ring formation of perhydrothiazocine from chlorambucil and DMSO 
creates a green fluorescent derivative. The accumulation of chlorambucil-protein 








Figure 44: Photocatalyzed luminescent ANXA5-CMB (green) binding L1210 
leukemia. The UV catalyzed heterocyclic ring formation of perhydrothiazocine 
from chlorambucil and DMSO creates a fluorescent derivative. The accumulation 
of chlorambucil-protein conjugate to L1210 cells was demonstrated in this manner. 
Cells were incubated with chlorambucil – annexin A5 conjugate briefly (3 h), and 
then fixed in 4% paraformaldehyde. Samples were then incubated under UV light 
(20 W for 1 h) to develop fluorescence. Cells were then imaged.  
 
Acute Lymphocytic Leukemia 
Having confirmed the localization of ANXA5-CMB to L1210 leukemia 
cells, we undertook an assay of bioconjugate cytotoxicity. The viability of L1210 
leukemia cancer cells treated with either chlorambucil or a chlorambucil-protein 
conjugate was assayed after 24 hours (Figure 45). Cells were incubated with 
chlorambucil (CMB) or chlorambucil-annexin A5 conjugate (ANXA5-CMB). The 
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(circles) (P ≤ 0.005). The 50 % cytotoxic concentration was 10 µM for CMB and 1 
µM for ANXA5-CMB, a 10-fold difference.  
 
 
Figure 45: Comparative cytotoxicity of L1210 leukemia. The viability of L1210 
leukemia cancer cells treated with either chlorambucil (circles) or a chlorambucil-
protein conjugate (squares) was assayed by alamarBlue after 24 hours. Cells were 
incubated with chlorambucil (CMB) or chlorambucil-annexin A5 conjugate (CMB-
ANXA5). The conjugate (circles) was significantly more potent than the free 
chlorambucil (squares). The full viability curve of chlorambucil was truncated by 
physical limitations (solubility ~300 mM). Data depicted as mean ± SE (n = 8). 
Error bars omitted for clarity if SE was smaller than the point symbol. 
 
 



















   99 
 
 
Following initial results in the L1210 model of leukemia, the cytocidal 
activity of the ANXA5-CMB conjugate was determined in a second cell mode 
using the macrophage derived lymphocytic lymphoma cell line P388 (Figure 46).   
The viability of P388 lymphoblastic lymphoma cancer cells treated with either 
chlorambucil or a chlorambucil-protein conjugate was assayed after 24 hours. 
Again in a second model of leukemia, the conjugate (circles) was significantly more 
potent than the free chlorambucil (squares)(P ≤0.005). The CC50 was 60 µM for 











Figure 46: Comparative cytotoxicity of CMB (circles) and ANXA5-CMB 
(squares). The viability of P388 lymphoblastic lymphoma cancer cells treated with 
either chlorambucil or a chlorambucil-protein conjugate was assayed by 
alamarBlue after 24 hours. Cells were incubated with chlorambucil (CH) or 
chlorambucil-annexin A5 conjugate (ANXA5-CMB). The conjugate (circles) was 
significantly more potent than the free chlorambucil (squares). The full viability 
curve of chlorambucil was truncated by physical limitations (solubility ~300 mM). 
Data is presented as the mean ± SE (n = 12). Error bars omitted for clarity if SE 




























The cytocidal activity of ANXA5-CMB was established in two models of 
acute lymphocytic leukemia. In the L1210 and P388 models CMB was a poor 
inducer of cell death. The full cytotoxicity profile of CMB was unable to be 
constructed due to solubility limitations. The chemotherapeutic CMB is insoluble 
in water. Even with the aid of a dimethyl sulfoxide cosolvent, the highest 
concentration of CMB aachieved as only 300 µM. We note that the ANXA5-CMB 
conjugate was fully soluble in water and not precipitation was observed at 
concentrations of CMB as high as 10 µM.   
Following promising in vitro results, we undertook an in vivo assay of 
ANXA5-CMB antineoplastic activity using the L1210 cell line in a mouse model 









Figure 47: ANXA5-CMB dependent survival increase in a L1210 model. The 
survival of 6 week old male DBA mice inculcated with 105 L1210 leukemia cells 
was monitored for 7 weeks. Mice received either daily doses of 20 μg of 
chlorambucil as a free agent or as part of a protein – drug conjugate, which started 
2 days after innoculation. The annexin A5 – chlorambucil conjugate performed 
significantly better than free chlorambucil, significantly improving survival. Data 
presented as mean ± SE (n = 9).   
 
Chlorambucil (median survival: 29 d) significantly increased the survival 
of mice bearing L1210 lymphocytic leukemia (median survival 29 d) as measured 
by the Mantle-Cox Test (P = 0.0004) and the Gehan-Breslow-Wilcoxon Test (P = 
0.0005). Additionally, the protein conjugate ANXA5-CMB (median survival: 31 d) 
significantly increased the survival of mice bearing L1210 tumors (median survival 
29 d) as measured by the Mantel-Cox Test (P = 0.0004) and the Gehan-Breslow-
Wilcoxon Test (P = 0.0007). While the ANXA5-CMB conjugate did not 
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significantly increase survival when compared to CMB as measured by the Mantel-
Cox Test ( P = 0.08) or the Gehan-Breslow-Wilcoxon Test ( P = 0.12), one mouse 
appeared to have full tumor regression and to date has survived greater than 100 
days tumor free.  Furthermore, an analysis of the confidence intervals reveals that 
an increase in median survival of 1 day in the ANXA5-CMB group would have 
likely yielded significant differences between the two groups. Significance could 
easily be achieved by increasing the number of animals or increasing the dose of 
CMB-ANXA5. Further work is needed to optimize the in L1210 in vivo model.  
 
Adverse Effects 
The ANXA5-CMB conjugate has significant antineoplastic activity both in 
vitro and in vivo. A typical side effect of potent mustard derived agents is lowered 
white blood cell counts (WBCC). Lowered WBCC or leukopenia, is a deadly side 
effect. After observing ANXA5-CMb cytocidal activity in both macrophage and B-
cell derived tumor cell lines, we investigated the effect of the conjugate on healthy 
mouse WBCC (Figure 48). We assayed the effect of ANXA5-CMB on WBCC male 
DBA/2 mice of 10 weeks of age treated daily with 20 μg of ANXA5-CMB. No 
changes in WBCC (purple cells) was observed in conjugate treated animals (left) 










Metastatic Breast Cancer 
Having observed ANXA5-CMBN cytocidal activity in nonsolid murine 
tumor models of lymphocytic lymphoma, we furthermore assayed the antitumor 
activity of the conjugate in several solid tumor models. First, the viability of EMT6 
breast cancer cells treated with either chlorambucil or a chlorambucil-protein 
conjugate was assayed after 24 hours (Figure 49). Cells were incubated with 
chlorambucil (CMB) or chlorambucil-annexin A5 conjugate (ANXA5-CMB). The 
conjugate (squares was significantly more potent than the free chlorambucil 
(circles).  
Figure 48: Comparison of control (left) and treated (right) WBCC in 
thin-film blood smears. The chlorambucil- annexin ANXA5 conjugate 
does not induce leukopenia (low WBCC) in mice. Mice treated daily 
with 20 μg of chlorambucil conjugate (left) did not have statistically 








Figure 49: Comparative cytotoxicity of CMB and ANXA5-CMB for EMT breast 
cancer cells. The viability of EMT6 breast cancer cells treated with either 
chlorambucil or a chlorambucil-protein conjugate was assayed by alamarBlue 
assay after 24 hours. Cells were incubated with chlorambucil (CH) or chlorambucil-
annexin A5 conjugate (ANXA5-CMB). The conjugate (circles) was significantly 
more potent than the free chlorambucil (squares) ( p ≤ 0.005). The full viability 
curve of chlorambucil was truncated by physical limitations (solubility ~300 mM). 
Data is presented as mean ± SE ( n = 12). Error bars omitted for clarity if SE was 
smaller than the point symbol.  
The in vitro cytocidal activity of ANXA5-CMB was further characterized 
in the triple-negative drug resistant 4T1 breast cancer cell line (Figure 50).  The 
viability of 4T1 breast cancer cells treated with either chlorambucil or a 
chlorambucil-protein conjugate was assayed after 24 hours. Cells were incubated 
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with chlorambucil (CMB) or chlorambucil-annexin A5 conjugate (ANXA5-CMB). 




Figure 50: Comparative cytotoxicity of CMB  and ANXA5-CMB. The viability of 
4T1 breast cancer cells treated with either chlorambucil or a chlorambucil-protein 
conjugate was assayed by alamarBlue assay after 24 hours. Cells were incubated 
with chlorambucil (CH) or chlorambucil-annexin A5 conjugate (ANXA5-CMB). 
The conjugate (circles) was significantly more potent than the free chlorambucil 
(squares) (p ≤ 0.005). The full viability curve of chlorambucil was truncated by 
physical limitations (solubility ~300 mM). Data is presented as mean ± SE ( n = 
12). Error bars omitted for clarity if SE was smaller than the point symbol. 
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We observed ANXA5-CMB dependent cytocidal activity in the 4T1 and 
EMT6 models of breast cancer. In contrast to ANXA5-CMB, we observed very 
little cytotoxicity in the 4t1 or EMT6 tumor models with CMB alone. In the EMT6 
model, CMB dependent cytotoxicity was first observed at concentrations as high as 
10 µM. In the drug-resistant tumor line 4T1, CMB dependent cytotoxicity was first 
observed at doses of 20 µM. The drug CMB alone was only capable of reducing 
the viability of drug-resistant 4T1 cultures by half at its maximum solubility limit 
(200 µM). In contrast to CMB alone, the conjugate ANXA5-CMB was much more 
potent. In the EMT6 cell line cytotoxic effects were first observed at doses as small 
as 0.1 µM. In the 4T1 cell line cytotoxicity was observed at doses as low as 1 µM.  
Evaluation of the therapeutic efficacy of the ANXA4-CMB conjugate was 
performed in BALB/cj mice bearing orthotopic tumors (Figure 51). The conjugate 
almost completely halted tumor growth for 18 days. This study was repeated with 
the addition of a group treated by free CMB (Figure 52). The tumor volumes were 
significantly smaller by day 9 for the mice treated by the conjugate, compared to 
treatment by free CMB. The dose of CMB in the ANXA5 conjugate (0.5 mg/kg) is 
much lower then has been reported in previous studies of treating tumors with free 
CMB (5-20 mg/kg) [113, 114]. Based on the in vitro data (Figure 50) it appears 
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activity. Even a tripling of the conjugate would give a lower CMB dose then was 
previously employed.  
 
Figure 51: ANXA5-CMB suppression of 4T1 breast cancer tumor growth. The 
growth of 4T1 metastatic breast cancer was monitored in mice (n = 5) over a period 
of several weeks. Balb/cj mice of 8 weeks of age were inoculated with an orthotopic 
injection of 105 4T1 cells in the mammary fat pad on day 0. The following day mice 
received 10 μg of chlorambucil as part of a protein – drug conjugate. The annexin 
A5 – chlorambucil conjugate was administered daily for the duration of the study. 
Mouse tumor volumes were recorded twice weekly and tumor volume was 
determined by the formula [ V=1/2*L*W^(2 )]. Data is presented as mean ± SE ( n 
= 12).  
































Figure 52: ANXA5-CMB suppression of 4T1 breast cancer tumor growth with the 
addition of a CMB treatment group. The growth of 4T1 metastatic breast cancer 
was monitored in mice (n=5) over a period of several weeks. Balb/cj mice of 8 
weeks of age were inoculated with an orthotopic injection of 105 4T1 cells in the 
mammary fat pad on day 0. The following day mice received 10 μg of chlorambucil 
as part of a protein – drug conjugate. The annexin A5 – chlorambucil conjugate was 
administered daily for the duration of the study. Mouse tumor volumes were 
recorded twice weekly and tumor volume was determined by the formula [ 
V=1/2*L*W^(2 )]. Data is presented as mean ± SE ( n = 12).   
 
Conclusion 
The novel cytocidal bioconjugate (ANXA5-CMB) comprised of the protein 
annexin A5 (ANXA5) and the alkylating agent chlorambucil (CMB) possesses 
significant cytotoxic activity. We characterize the resulting conjugate by both SDS-
Page and quantitative fluorescent spectroscopic analysis of CMB. We then 
successfully demonstrate the activity of the characterized conjugate in four separate 
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models of cancer, two of which we further test in orthotopic murine models. We 
conclude that the ANXA5-CMB conjugate has significant anticancer activity both 
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Chapter 5: Preliminary Studies 
 
Chapter 5A: Heating of Single-Walled Carbon Nanotubes by 
Very High Frequency Radiowaves 
 
Abstract 
Very high frequency (VHF) radio waves (30-150 MHz) heat 6,5 chiral single-




Very high frequency (VHF) radiation heats semiconducting SWCNTs by 
dipole induced phonon generation. Electromagnetic radiation induces the formation 
of charge dipoles within SWCNTs. These dipoles generate a loading force which 
mechanically deform the SWCNTS. The deformation of the SWCNT in response 
to this force can be crudely modeled using either the Euler-Bernoulli or 
Timoshenko macroscopic beam deformation theorems [115-117]. The transient 
localized deformation of the carbon lattice within the SWCNT then moves along 
the carbon nanotube. The moving wave of stressed carbon atoms is referred to as a 
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along the SWCNT [118]. The phonons then are transferred to the surroundings 
where they deposit their energy creating heat. The specific heating of SWCNTs in 
response to VHF radiation has been employed previously in such application as 
tumor thermal ablation [119].  
The VHF radiation dependent heating of SWCNTs by dipole induced 
phonon generation is primarily a factor of nanotube chirality, nanotube length, and 
the VHF excitation frequency. While the excitation of SWCNTs by VHF and the 
resulting heating can be modeled by theorems such as the Euler-Bernoulli beam 
theory, it is important to note that these models only serve as estimations of 







Equation 1: Euler-Bernoulli's vibrational beam theory.  The resonance frequency 
(fresonant) can be approximated by this model. Where β1 is a constant, L is the length, 
Do and Di are the inner and outer diameters respectively, E is the Young’s modulus, 
and ρ is the density.  
 
Several factors contribute to the failure of the Euler-Bernoulli equation to 
accurately model SWCNTs response to VHF radiation. First, the Euler-Bernoulli 
equation was developed for macroscopic not nanoscopic mechanics. Second, 
SWCNTs are a heterogeneous mix of many species of nanotube.  The SG65i 
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chiral SWCNTs (Appendix D: Chiral Analysis).   The remaining characterizable 
mass fraction of the sample was predominantly (7,3), (9,4), (8,4), and (7,5) chiral 
nanotubes which accounted for another 35% of the total sample. The remaining 
26% of the sample consisted of species such as aamorphous carbon, 
noncharacterizable nanostructures, carbon black, and cobalt-molybdenum catalyst. 
Each species within the SG65i sample will respond differently to VHF as predicted 
by the Euler-Bernoulli model. Third, the length of each chiral species of SWCNT 
is not uniform. Initially, the length of nanotubes within the SG65i samples varied 
from 0.5-1.0 µM. Sonication of the SWCNTs during the synthesis of the liquid SDS 
suspension damages the nanotubes, decreasing the mean length of the SWCNTs.  
Finally, the nanotubes themselves are not pristine beams as assumed by the model. 
The SWCNTs have numerous point defects where the carbon matrix has been 
oxidized, breaking the uniformity of the beam decreasing the effective length of the 
modeled beam. These factors all contribute to deviations in the Euler-Bernoulli 
model. Therefore, it is necessary empirically observe the SG65i heating response 
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Materials and Methods 
 
Materials 
Sodium phosphate, and sodium dodecyl sulfate (SDS) were from 
Mallinckrodt Chemicals (Phillipsburg, NJ). SG65i single-walled carbon nanotubes 
were from CHASM Advanced Materials (Canton, MA). Characterization of the 
SWCNTs can be found in Appendix D.  
 
System Analysis 
Electric field plates capable of supporting a 10 mm2 macro UV-cuvette were 
scavenged from a Comdel CX-600S ultra stable 13.56 MHz generator chosen for 
use based off of previous in house work [119]. Plates were placed in a parallel plate 
orientation using ultra dense polyethylene foam and 10 mm nylon bolts. The setup 
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Smith chart output) to determine the system’s intrinsic resistance and impedance 
between 30 and 120 MHz (Figure 53).  
 
Figure 53: Intrinsic reflection of the load.  The intrinsic reflection of the heating 
plates (load) as measured by the S11 coefficient on a network analyzer assuming a 
50 Ω connection.  
A narrow band Lumped element matching network (L-network) was chosen 
to match the plates (Figure 54) [120].  A series capacitor and shunt inductor 
configuration were chosen for the L-network. Theoretical capacitor and inductor 
values were then calculated from PNA network analyzer data to impedance match 
the system (Re(z)=1; z=1) assuming a 50 Ω load (Figure 54) (Figure 55) (Figure 
56). Roller inductors (100-1500 nH) and butterfly capacitors (2.0-22.4 pF) were 
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sourced from Rokwell/Collins and obtained through Surplus Sales of Nebraska 
(Omaha, Nebraska). 
 
Figure 54: Radiofrequency setup.  Electrical diagram of the power supply, signal 







𝑅 + 𝑋 −𝑍 ∗ 𝑅
𝑅 +𝑍
 
Equation 2: The L-network variable 'B' used as placeholder in several equations is 
a function of initial system reactance (𝒁𝑶), frequency (f), load resistance (𝑹𝑳), and 
















Equation 3: The deal L-network capacitor value as a function of initial system 
reactance (𝒁𝑶), frequency (f), load resistance (𝑹𝑳), load reactance (𝑿𝑳) and the 









2 ∗ 𝜋 ∗ 𝑓 ∗ 𝐵
 
Equation 4: The ideal L-network inductor value as a function of system reactance 




Figure 55: Ideal theoretical inductor values. The ideal inductor values for a L-
network that matches the heating plates to the generator were determined from the 
intrinsic reflextion.      
 






























Figure 56: Ideal theoretical capacitor values. The ideal capacitor values for a L-
network that matches the heating plates to the generator were determined from the 




The assembled network and plate system was then tested using the PNA 
network analyzer (transmittance mode) to confirm load match and verify theoretical 
ideal frequency calculations (Figure 57). The network and plates were then 
connected to an Agilent 4 -channel oscilloscope via a direction coupler in order to 
directly monitor voltage mismatch. The coupled system was again tested using the 
PNA network analyzer to insure the directional coupler and oscilloscope did not 
shift the ideal transmittance frequency. The plates and network were then attached 



























   119 
 
 
to the RF system consisting of a BK precision XLN6024 60 V programable power 
supply (Yorba Linda, Ca), a HD30664 Class A 20 W linear amplifier (Denver, CO), 
and a HP 8648A signal generator (Las Angeles, CA).  
 
 
Figure 57: Network matching plates (green arrow) with an attached L-network (red 
arrow). The field plates initially were unmatched (green arrow). A L-network 
consisting of a series capacitor and a shunt inductor was constructed and attached 
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Results and Discussion 
A cuvette holding 3 mL of 195 mg/mL SWCNT from was placed between 
the field plates. The DC power supply was set to 28 V and 4.5 A; current leakage 
of 3.9 A was observed during operation. The signal generator was keyed to the ideal 
frequency measured during network matching using the PNA network analyzer, 
and a -60 dB signal was triggered.  The oscilloscope was observed to monitor 
voltage mismatch while a frequency sweep +/- 20 MHz was performed to 
empirically optimize voltage mismatch. At this stage voltage mismatches (in: out) 
of 4:1 were considered ideal. With the proper frequency identified and voltage 
mismatch minimized, function generator input was increased to -5 to -4 dB over 30 
seconds. Samples were then irradiated for 8-10 minutes and temperature was 










Figure 58: Heating of SWCNTs by VHF radiation. A sample of SWCNTs (195 
mg/L) was irradiated at a power of 15 watts for 8-10 minutes and temperature was 
recorded. Samples excited at 31 and 65 MHz were irradiated using the HD30664 
linear amplifier, and the sample at 13.6 MHz was irradiated using a Comdel CX-
600S amplifier.    
 
A twofold increase in heating was observed as the frequency increased from 
31 MHz to 65 MHz. This change corresponded to a heating rate increase of 0.25 
°C/min at a power of 15 W over the measured spectra.  Normalizing the heating 
rate increase to power, we observe a heating rate of 0.016 °C/W.  
 


































VHF radiation at a power of 15 W between a frequency of 13 and 65 MHz 
heated aqueous suspended samples of SG65i SWCNTs in SDS buffer at a 
maximum rate of 0.52 °C/min. The observed heating rate was less than that 
observed previously. This difference may be due to experimental protocol 
differences or deviations from the assumed Euler-Bernoulli model of heating. 
Further observations at additional frequencies are necessary to more accurately 
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Chapter 5B: Synergistic Enhancement of the Cytocidal Activity of 
Docetaxel by Single-Walled Carbon Nanotubes 
 
Abstract 
Here we present a chemotherapeutic delivery agent comprised of 6,5 single-
walled carbon nanotubes (SWCNTs) functionalized with the anticancer drug 
docetaxel (DTX). The chemotherapeutic was synthesized by labeling SWCNTs 
with the highly hydrophobic taxane, docetaxel, by antisolvent precipitation.  
Docetaxel loading was then assayed by methylene chloride extraction followed by 
absorbance spectroscopy. Having determined the loading efficiency of docetaxel, 
we proceeded to analyze the cytotoxicity of the resulting conjugate in several 
models of cancer. The SWCNT-DTX conjugate possessed increased anticancer 
activity compared either SWCNT or DTX alone. In this chapter we demonstrate the 
synthesis, analysis, and efficacy of SWCNT-DTX conjugate.  
 
Introduction  
Carbon nanotubes were first discovered by Sumio Iijima in 1991 and gained 
extensive attention due to their robust nature, large surface areas, ability to be 
functionalized, and drug-loading properties [121]. A number of in vitro and in vivo 
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unique stability, large surface area and ease of chemical functionalization make 
carbon nanotubes ideal drug delivery agents capable of efficiently loading a target 
therapeutic. The association of traditional chemotherapeutics with a carbon 
nanotube delivery vehicle confers several therapeutic benefits including improved 
drug solubility, enhanced stability, increased drug cytotoxicity, and increased 
tumor uptake.  While a diverse group of tumor killing agents including novel 
therapeutics such as folate receptor inhibitors, interfering RNA, and cell toxins have 
been used in association with nanotube delivery, the vast majority of nanotube 
associated chemotherapeutic agents belong to the taxane, platinum or anthracycline 
family.  
Carbon nanotubes been used as delivery agents for chemotherapeutics of 
the anthracycline family. Originally isolated from cultures of Streptomyces 
peucetius in the early 1960s by multiple independent groups, daunorubicin, the 
founding member of the glycoside anthracycline family was effective against a 
wide variety of cancer types, most notably childhood leukemia [122, 123]. While 
nanotube associated daunorubicin has been employed by several groups, the 
majority of anthracycline-nanotube research has focused on the more potent 
anthracycline derivative doxorubicin [124-129]. Another common group of agents 
whose therapeutic potential can be enhanced by nanotubes is the platinum agent 
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founding member cisplatin are potent cytostatic agents effective in a wide variety 
of tumor types especially when employed with SWCNTs [130-133].   
Since their first documented in vitro use in 1971, the taxane family of 
cytostatic agents has become the standard of care for many types of cancer [134]. 
The taxane family of cytostatic agents including the founding member of the 
family, paclitaxel, and derivatives such as docetaxel are some of the most effective 
anticancer chemotherapeutics in the clinical environment. [135]. However, despite 
their tremendous clinical significance, the clinical use of taxanes is hampered by 
three critical drawbacks. First, members of the taxane family are almost completely 
insoluble in water, necessitating the use of solubilizing agents such as polysorbate 
or castor oil derivatives to facilitate intravenous administration. Second, while these 
solubilizing excipients enable the aqueous administration of taxanes, they have 
significant effects on the bioavailability of administered taxanes [136].  Finally, 
only a fraction of a given taxane dose actually reaches neoplastic tissue.  Harnessing 
the unique chemical and physical properties of carbon nanotubes as delivery agents, 
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Materials and Methods 
Materials 
Bovine serum albumin (BSA), Alamar Blue reagent, Triton X-100, EDTA, 
TPCK, β-mercaptoethanol, PMSF, and Tris-acetate-EDTA buffer were from 
Sigma-Aldrich (St Louis, MO). Sodium phosphate and sodium dodecyl sulfate 
(SDS) were from Mallinckrodt Chemicals (Phillipsburg, NJ). Docetaxel was from 
TCI America. HPLC grade ethanol was from Acros Organics (Waltham, MA). 
Antifade reagent Fluoro-gel, and Slide-A-Lyzer dialysis cassettes (3.5 kDa) were 
from Thermo Fisher Scientific (Waltham, MA). The 2 and 100 kDa dialysis 
membranes were from Spectrum Laboratories (Rancho Dominguez, CA). Roswell 
Park Memorial Institute cell medium (RPMI-1640) and Hank’s balanced salt 
solution were from ATCC (Manassas, VA). Fetal bovine serum (FBS) was from 
Atlanta Biologicals (Lawrenceville, GA). Trypton, yeast extract, and kanamycin 
monosulfate were obtained from Alfa Aesar (Haverhill, MA). Sodium hydroxide, 
potassium chloride, and sodium chloride were from VWR inc (Radnor, PA). HRV-
C3 protease was from Sino biologics (Portland, OR). Single-walled carbon 
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Cell lines and Cell Culture 
Cell lines and cell culture were done as previously described in chapter 2 and 
Chapter 4. 
 
Cell Viability Analysis 
 Cells were incubated with chemotherapeutic as described and then cell 
viability was assayed by alamarBlue assay. Cells were incubated with fresh media 
containing 10% (v/v) alamarblue for 3 hours and then fluorescence was assayed at 
570:580; ex; em). Viability of treated samples was compared to an untreated 
control. A more detailed procedure was previously described [46]. 
 
Conjugate Synthesis 
The SWCNT-DTX conjugate was synthesized by antisolvent precipitation 
of DTX. A mixture of 5 mg of SWCNT and 20 mg DTX in 500 µL of anhydrous 
EtOH was mixed in an JP-890 ultrasonic bath for 15 m while dropwise phosphate-
buffered saline solution was added to a total volume of 3 mL. The mixture was then 
pulsed 10 times by a Fischer 50-sonic dismembrator at 400 W for 10 s each time. 
The SWCNT-DTX conjugate was isolated by centrifugation at 10,000 g for 15 
minutes. The pellet was then briefly washed with anhydrous EtOH followed by 









Analysis of the SWCNT-DTX conjugate was done by absorbance 
spectroscopy. SWCNT concentration was determined as previously described 
(Chapter 3). DTX was isolated from the SWCNT-DTX conjugate by methylene 
chloride - water solvent biphasic extraction. The DTX within the methylene 
chloride was then quantified by absorbance spectroscopy of the maximum 
absorbance between 200-300 nm. The detailed spectroscopic examination of DTX 
in methylene chloride and various other solvents can be found in (Appendix E).  
 
In Vitro Cytotoxicity Studies 
The SWCNT-DTX conjugate was gently suspended in EtOH by gently 
vortexing. Viability assays were performed using the AlamarBlue assay as 
described in “Chapter 2”.  
 
Results and Discussion 
Initial Observations 
The synergistic interaction between DTX and SWCNTs was first observed 
in vitro in the B16F10 model of melanoma (Figure 59). Cells were accidentally 




   129 
 
 
mg/L). In groups receiving SWCNTs and DTX, a marked increase in cell 
cytotoxicity was observed. We hypothesized that SWCNTs were synergistically 
enhancing DTX cytotoxicity.    
 
Figure 59: Nanoparticle-Drug synergistic cytotoxicity. The presence of EtOH 
dispersed SWCNT (5 mg/L) synergistically enhances DTX (10 μM) cytotoxicity. 
B16F10 melanoma was cultured with DTX and SWCNT for 24 h. The combination 
of DTX and SWCNT was significantly more toxic that DTX alone, as indicated by 
‘ * ‘ (P ≤ 0.05). Data is shown as the mean ± SE (n = 3).   
 
In a more detailed study, neither docetaxel or SWCNT significantly reduced 
the viability of B16F10 cell cultures over 24 hours (Figure 60). However, the 
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cytotoxicity (P ≤ 0.05). We conclude that SWCNT synergistically enhance DTX-
mediated B16F10 cytotoxicity.  
 
Figure 60: Nanoparticle-Drug synergistic cytotoxicity. The presence of aqueous 
dispersed SWCNT (5 mg/L) synergistically enhances DTX (10 μM) cytotoxicity. 
B16F10 melanoma was cultured with DTX and SWCNT for 24 h. The combination 
of DTX and SWCNT was significantly more toxic that DTX or SWCNTs alone as 
indicated by ‘ *’  (P ≤ 0.05). Data is shown as the mean ± SE (n = 3).   
 
Conclusion 
Single-walled carbon nanotubes synergistically enhance the toxicity of 
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that the independent presence of both DTX and SWCNTs in solution produces a 
marked increase in the cytotoxicity of both components. In an attempt to harness 
this observed phenomenon, a SWCNT-DTX conjugate was synthesized by 
antisolvent precipitation. We characterized the DTX loading by absorbance 
spectroscopy following methylene chloride extraction. Preliminary in vitro data in 
the MB49 cell line suggests that the SWCNT-DTX conjugate is more toxic than 
free DTX. While we observed marked anticancer activity in the MB49 cell line, 
further work is necessary to characterize the synthesis and in vitro anticancer 






















Chapter 5C: Interaction of Annexin A5 and Drug Resistance in 
the Presence of the Selecting Drug  
 
Abstract 
Phosphatidylserine (Ptd-L-Ser) dependent annexin A5 (ANXA5) binding to 
wildtype L1210 and drug resistant L1210r leukemia cells is modulated by the 
presence of subtoxic doses (10 µM) of chlorambucil (CMB). Drug resistance was 
induced in the L1210 cell line by culture with CMB (10 µM) for 2 months; creating 
a drug resistance subline, L1210r. The expression of Ptd-L-Ser was assayed in both 
L1210 and L1210r cells by cytometric quantification of fluorescent FITC-ANXA5 
binding. While we observe increases in Ptd-L-Ser expression in the L1210r versus 
L1210 cell lines, this relationship was inverted in the presence of chlorambucil (10 









Many tumor cell lines are characterized by increased Ptd-L-Ser expression 
[140-142]. The expression of Ptd-L-Ser is intrinsically tied to the pathological 
progression of cancer. All lethal tumors share several etiological hallmarks 
including: uncontrolled proliferation, failure of apoptosis, angiogenic activity, 
evasion of the immune system, and metastasis.  [12, 13, 17-20, 31]. The expression 
of Ptd-L-Ser is intrinsically tied to oncogenesis and metastasis. Furthermore, the 
expression of Ptd-L-Ser is a byproduct of drug resistance.  
One of the principle mechanisms of acquired drug resistance in tumors is 
drug efflux by cell membrane transporters. The transporters, primarily of the ATP-
binding cassette (ABC) transporter family, remove chemotherapeutics from the cell 
[143-148]. Increased expression and activity of ABC-transporters confers drug 
resistance to cancerous cells.  The natural role of these transporters is the transport 
of hydrophobic molecules across the lipid bilayer of the cellular membrane. 
Specifically, many ABC-transporters act as flippase, floppase and scramblases 
maintaining Ptd-L-Ser asymmetry in healthy cells [149-152]. We hypothesize an 
increase in Ptd-L-Ser would be observed during the acquisition of ABC-transport 










Constitutive Expression of Ptd-L-Ser 
The constitutive expression ot Ptd-L-Ser on cancer cells can be observed by 
flow cytometric analysis using the natural ligand of Ptd-L-Ser, ANXA5. Cancerous 
L1210 cells express more Ptd-L-Ser than healthy rat mesenchymal stem cells 
(rMSCs) as observed by ANXA5 binding (Figure 61).  
 
Figure 61: Ptd-L-Ser expression in rMSCs (left) and wildtype L1210 leukemia 
cells (right).  
 
Drug Resistance 
Wildtype L1210 leukemia cells were transformed by continuous exposure 
to subtoxic doses of chlorambucil (10 µM) for 2 months.  This selection produced 
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of low concentrations of Ptd-L-Ser on wildtype L1210 leukemia cells is heightened 
by chlorambucil resistance in L110r cells (Figure 62).   
 
 
Figure 62: Drug resistant L1210r cells (right) express more Ptd-L-Ser than 
wildtype L1210 cells (left).  
 
Drug-Drug Resistance Interaction 
We assessed the interactions between CMB and CMB resistance on the 
expression of Ptd-L-Ser in L1210 leukemia. Ptd-L-Ser dependent ANXA5 binding 
was assessed in both wildtype and resistant L1210 leukemia cells in the presence 
of drug supplemented or drug free media (Figure 63). We observed that wildtype 
L1210 cells significantly upregulate Ptd-L-Ser expression in subtoxic doses of 
CMB (top left). Interestingly, we observed the same relationship in drug resistant 
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continuatively express more Ptd-L-Ser than wildtype cells in drug free media 
(bottom left). Surprisingly, this relationship was revered in presence of 
chlorambucil (bottom right). It is likely that this relationship results from the 
competition between hydrophobic chlorambucil and Ptd-L-Ser for ABC-










Figure 63: Effects of CMB and CMB resistance on Ptd-L-Ser expression in L1210 
leukemia. The relative expression of Ptd-L-Ser as measured by fluorescent ANXA5 
accumulation was assayed in wildtype and drug resistant L1210 cells in the 
presence of media with or without supplemental drug (D+, D-) All represented 
groups were significantly different (P ≤ 0.05). Data is shown as the mean ± SE (n 



































































































































































Phosphatidylserine (Ptd-L-Ser) dependent Annexin A5 (ANXA5) binding 
to wildtype L1210 and drug resistant L1210r leukemia cells is modulated by the 
presence of subtoxic doses (10 µM) of chlorambucil (CMB). Drug resistance was 
induced in the L1210 cell line by culture with CMB (10 µM) for 2 months, creating 
a drug resistance subline, L1210r. The expression of Ptd-L-Ser was assayed in both 
L1210 and L1210r cells by cytometric quantification of fluorescent FITC-ANXA5 
binding. The constitutive expression of Ptd-L-Ser on wildtype L1210 was 
heightened in chlorambucil resistant L1210r. Interestingly, this relationship was 
inverted in the presence of chlorambucil. Further work is necessary to establish  
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Chapter 5D: Bactericidal Activity of a Novel Protein-Antibiotic 
Bioconjugate  
Abstract 
Here we present antibacterial activity of a novel annexin A5 (ANXA5) 
derivative. The ANXA5 derivative is a novel bioconjugate comprised of the protein 
annexin A5 (ANXA5) and the penicillin derivative ampicillin (AMP). The 
extracellular antibacterial activity of the annexin A5 – ampicillin (ANXA5-AMP) 
conjugate was assayed in E. coli and NTHI bacteria.  Surprisingly, the antibiotic 
conjugate, ANXA5-AMP also possessed significant antitumor activity as assayed 
in the EMT6 murine model of metastatic breast cancer.  
 
Introduction 
Bacterial infections can be classified as either intracellular or extracellular, 
depending on the location of the pathogen. Notable intracellular bacterial pathogens 
include Legionnaires disease, tuberculosis, and the plague. Treatment of these 
diseases is challenging due to the location of the bacteria within the cell. The 
mammalian cell membrane serves as an additional protective barrier for the 
pathogenic bacteria, blocking antibiotics.  One possible mechanism to enhance the 
delivery of an antibiotic to infected cells is by conjugation of the antibiotic to a 
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express phosphatidylserine [31]. The expression of Ptd-L-Ser on infected cells may 
be a target for targeted antibiotic delivery.  
 
Materials and Methods 
Annexin A5 Production 
Recombinant mCGL-ANXA5 was produced and isolated by His-tag 
chromatography, and activity was confirmed by a chromatographic assay as 
previously described (Chapter 1). The experimental procedure is provided in 
Appendix A. Purity was confirmed by SDS-PAGE. Samples were confirmed 
endotoxin free by limulus amoebocyte lysate assay.  
 
Conjugate Synthesis 
Synthesis of the conjugate was performed in a process similar to that 
previously described (Chapter 4). However, several key differences in reaction 
chemistry were necessitated by the presence of both a primary amine and a 
carboxylic group within AMP.  First, AMP (30 mg/mL) was activated by EDC (3 
mg/mL). This was to account for the loss of AMP by AMP-AMP crosslinking. All 










Analysis of Conjugate 
The concentration of ampicillin (α-aminobenzylpenicillin) within the 
ANXA5-AMP conjugate can be determined by fluorescent spectroscopy [155]. 
Standards of penicillin in phosphate buffer supplemented with 1% formaldehyde 
were acidified with HCl acid (pH 2) and then incubated at 98 °C for 1 hour to 
catalyze the production of α-aminobenzylpenicillenic acid. This derivative of 
ampicillin is fluorescent (ideal; 346/422 ex/em). Samples were then neutralized 
with NaOH (pH 7.4). Fluorescent analysis (360/460 ex/em) was capable of 








Figure 64: Fluorescent standard of ampicillin derivative α-
aminobenzylpenicillenic acid. The concentration of ampicillin (α-
aminobenzylpenicillin) can be determined by fluorescent spectroscopy. Standards 
of penicillin were acidified with HCl acid (pH 2) and then incubated at 98 °C for 1 
hour to catalyze the production of α-aminobenzylpenicillenic acid. This derivative 
of ampicillin is fluorescent (ideal; 346/422 ex/em). Samples were then neutralized 
(pH 7.4). Fluorescent analysis of standards (measured; 360/460 ex/em) was capable 
of detecting small concentrations of ampicillin (7 μg/mL). Data is shown as mean 
± SE (n = 3).   
Cell Lines and Cell Culture 
EMT6 breast cancer cells from ATCC (Manassas, VA) were cultured in 
Waymouth’s MB 752/1 medium with 2 mM L-glutamine supplemented with 15% 
fetal bovine serum (FBS). All cells were grown at 37 ° C and 100% humidity under 
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5 % CO2. All cells were passaged using 0.25 % (w/v) Trypsin  in 0.53 mM EDTA. 
E. coli strain BL21(DE3) from Thermo Fisher Scientific (Waltham, MA) were 
cultured in LB broth at 37 ° C.  Non-typable Haemophilus influenzae (NHTi) from 
BEI: NRAID (Manassas, VA) was cultured on chocolate agar or in brain-heart 
infusion broth at 37 ° C. NTHi cultures were supplemented with factors V and X 
[156]. 
 
Results and Discussion 
Extracellular Bactericidal Assay 
The antibacterial activity of ANXA5-AMP was first assayed in E. coli.  E. 
coli (strain:BL21(DE3)) was cultured in antibiotic free LB medium as previously 
described [6]. Cultures were supplemented with AMP or ANXA5-AMP and growth 
was monitored for 24 h (Figure 65).  The ANXA5-AMP conjugate significantly 
reduced E. Coli growth compared to free AMP. In addition to work with AMP 
derivatives of ANXA5, we observed that other therapeutic ANXA5 derivatives 
such as ANXA5-mCGL possessed antibacterial activity against both intracellular 
and extracellular bacteria (Appendix: Antibacterial Assay). This is interesting 
because the E. coli membrane contains little Ptd-L-Ser [157, 158] . Further work is 
necessary to identify the Ptd-L-Ser independent mechanisms resulting in 








Figure 65: Antibacterial activity of ampicillin and ampicillin-annexin A5 
conjugate. The ANXA5-AMP conjugate significantly reduced E. coli growth 
compared to free AMP (P ≤ 0.05). Data is represented as mean ± SE (n = 5).   
In a more in depth assay, the antibacterial activity of the ANXA5-AMP 
conjugate was assessed in the NTHi model of infection. The viability NTHi was 
determined by serial dilution and plate culture (Figure 66). Samples treated with 
either AMP or ANXA5-AMP conjugate were incubated for 36 h. Following 
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antibacterial activity of the conjugate was more then 10-fold more potent than that 
of free ampicillin. 
 
 
Figure 66: Comparative bactericidal activity of ampicillin and conjugate. The 
viability nontypable-Haemophilus influenza was determined by serial dilution and 
plate culture. Samples treated with either ampicillin (AMP, squares) or protein-
antibiotic conjugate (AMP-ANXA5, circles) were incubate for 36 hours with 
antibiotic or conjugate. Following incubation colonies were enumerated and 
compared to untreated controls. The antibacterial activity of the conjugate was 10 
to 10-fold more potent than that of free ampicillin. Data presented as mean ± SE (n 
= 8).  Error bars omitted for clarity if SE was smaller than the point symbol.  
 






















In addition to significant antibacterial activity the ANXA5-AMP conjugate 
possessed significant anticancer activity. EMT6 viability was monitored following 
a brief incubation (24 hours) with the ANXA5-AMP conjugate (Figure 67). 
Surprisingly, the conjugate has significant cytocidal activity in the EMT6 model 
(CC50: 100 µg/mL). Unlike most antibiotic derived chemotherapeutics, ampicillin 
is remarkably nontoxic. A lethal dose of ampicillin is 0.5% of an individuals 
bodyweight or about 310 g for an average 62 kg person [159].   No reduction in 








Figure 67: Toxicity of the conjugate in an EMT6 breast cancer model. The annexin 
V - ampicillin protein conjugate (AMP-ANXA5) possesses anticancer properties. 
The viability of EMT6 breast cancer cells was monitored following a brief 
incubation (24 hours) with the conjugate. The conjugate was capable of not only 
retarding cell growth but killing tumor cells as well. Data is presented as mean ± 
SE (n = 8).   
Conclusion 
The bioconjugate annexin A5 has significant activity against both intracellular 
and extracellular bacteria. In extracellular E. coli, the bioconjugate suppressed 
cell growth more efficiently than free AMP, even at doses 100-fold lower. In the 
intracellular model of pathogenic bacterial infection with NHTi,  the ANXA5-
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the antibiotic conjugate, ANXA5-AMP also possessed significant antitumor 
activity in the EMT6 murine model of metastatic breast cancer. Further work is 
needed to develop this novel bioconjugate in additional tumor models, and 
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Chapter 4E: Antineoplastic Carboplatin-ANXA5 Derivative 
Abstract 
Here we present a novel cytostatic bioconjugate (ANXA5-CBDCA) 
comprised of the protein annexin A5 (ANXA5) and the drug carboplatin (CBDCA). 
CBDCA was covalently linked to ANXA5 with a 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) intermediate linker stabilized by N-
hydroxysuccinimide (NHS).  Here we present the characterization and antitumor 
activity of the novel ANXA5-CBDCA conjugate. The conjugate was characterized 
by absorbance spectroscopy, and we confirmed the conjugation of carboplatin to 
the protein.  The cytocidal activity of the ANXA5-CBDCA bioconjugate was 
probed in vitro using the metastatic 4T1 breast and p53-/- ID8 ovarian cancer cell 
lines where we observed increased cytotoxicity compared to carboplatin alone. In 
vivo antineoplastic activity was determined in the 4T1 mouse model of late stage 
metastatic triple-negative drug-resistant breast cancer, where we observed large 
decreases in tumor volume.  
Introduction 
Carboplatin was linked to ANXA5 using 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS). 
Carboplatin is of prime clinical significance due to its remarkably broad anticancer 
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activity of a ANXA5 – chlorambucil conjugate. However, chlorambucil is very well 
tolerated, and relatively nontoxic. Carboplatin on the other hand, has significantly 
higher anticancer activity, at the cost of increased toxicity. This increased activity 
was the driving force behind the decision to select carboplatin as a potential 
ANXA5 - drug conjugate. While numerous groups have examined the activity of 
protein-carboplatin conjugate, no one to date has examined derivatives of 
carboplatin and annexin.  
 
Materials and Methods 
Materials 
Materials were sourced as previously described in chapters 1, 2 and 3.  
 
Cell Culture 
Drug resistant, triple-negative 4T1 breast cancer cells were transfected with 
tdTomato (Td) as previously described [6]. 4T1-Td breast cancer cells were 
cultured in Roswell Park Memorial Institute (RPMI-1640) medium supplemented 
with 10 % FBS and 1% penicillin/streptomycin antibiotics (100 U mL-1 and 100 
μg/mL-1 respectively). P53 double negative ID8 ovarian cancer cells were cultured 
in DMEM media supplemented with 10% fetal bovine serum(FBS), insulin-
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and 100 μg/mL-1 respectively). Cells were passaged using 0.25 % (w/v) trypsin in 
0.53 mM EDTA.  Cells were grown at 37 ° C and 100% humidity under 5 % CO2 
supplemented atmosphere.  
 
Synthesis of Conjugate 
Synthesis of the conjugate was performed in a process similar to that 
previously described (Chapter4). However, several key differences in reaction 
chemistry were necessitated by the absence of a carboxylic group on CBDCA. 
Instead of activating the carboxylic group of a drug, the carboxylic group on 
ANXA5 (2 mg/mL) was activated with EDC (0.12 mg/mL) and NHS (0.12 
mg/mL). The activation of ANXA5 carboxylic groups was done in in the presence 
of CBDCA (CBDCA 20 mg/mL).  
 
Analysis of Conjugate 
The concentration of CBDCA within the ANXA5-CBDCA can be 
determined by quantitative absorption spectroscopy [160]. Standards of CBDCA 
([Carboplatin]starting: 4.5 mg/mL) were solubilized in 30 mM sodium phosphate 
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Results and Discussion 
Loading Efficiency 
Typical molar loading ratios of CBDCA to ANXA5 of 3:1 (CBDCA: 
ANXA5) were observed. Due to the precipitation of multiple crosslinked 
byproducts, EDC/NHS synthesis was inefficient, generating significant precipitates 
with typical ANXA5 yields as low as 4.7%. 
 
In Vitro Cytotoxicity 
Conjugate cytotoxicity was determined by AlamarBlue assay as previously 
described (Chapter 2: Cytostatic Protein-Drug Conjugate).  
 
 
Results and Discussion 
Spectroscopy 
The extent of CBDCA functionalization within the ANXA5-CBDCA 
conjugate was determined by comparative absorption spectroscopy. Controlling for 
the absorbance of protein, we observed the unique UV-absorbance spectrum of 
carboplatin within samples of ANXA5-CBDCA. The concentration of ANXA5 was 
determined by Bradford assay as previously described (Chapter 2: Cytostatic 
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highly sensitive to reaction conditions but typical molar ratios of 3:1 (CBDCA: 




The cytocidal activity of ANXA5-CBDCA was first assessed in vitro in the 
4T1 metastatic breast cancer model. The viability of 4T1 breast cancer treated with 
either CBDCA or ANXA5-CBDCA conjugate was assayed after 24 hours (Figure 
68). The ANXA5-CBDCA conjugate was significantly more toxic than free 









Figure 68: Comparative cytotoxicity of carboplatin and conjugate. The viability of 
4T1 breast cancer cells treated with either carboplatin (squares) or carboplatin-
protein conjugate (circles) was assayed after 24 hours. The annexin A5 – 
carboplatin conjugate was more toxic than free carboplatin, killing virtually all cells 
at doses exceeding 100-fold less than free carboplatin. Data is shown as the mean 
± SE (n = 8)   
In a second in vitro model, the cytocidal activity of ANXA5-CBDCA was 
assayed in the ID8 p53-/- mouse model of ovarian metastatic cancer (Figure 69). In 
this second model, the carboplatin protein conjugate was significantly more toxic 
to cancer cells than free carboplatin. 























Figure 69: Comparative cytotoxicity of Carboplatin (squares) and conjugate 
(circles). The viability of ID8 p53-/- ovarian cancer cells treated with either 
carboplatin (squares) or carboplatin-protein conjugate (circles) was assayed after 
24 hours. The annexin A5 – carboplatin conjugate was more toxic than free 
carboplatin, killing virtually all cells at doses exceeding 100-fold less than free 
carboplatin. Data is shown as the mean ± SE (n = 8)   
 
Following successful in vitro testing, the in vivo activity of the ANXA5-
CBDCA conjugate was ascertained in a murine model of late stage metastatic breast 
cancer (Figure 70). Female balb/cj mice (n = 5) of 8 weeks of age were inoculated 
with an orthotopic injection of 105 4T1 cells in the IV mammary fat pad and tumors 
were allowed to develop for 23 days. Starting on day 23 mice were treated daily 
with 5 μg of CBDCA or ANXA5-CBDCA conjugate. Mouse tumor volumes were 
recorded twice a week and mouse tumor volume was determined by the formula : 
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[𝑉 = (𝑉 − 𝑉 ) = ∗ 𝐿 ∗ 𝑊 − ∗ 𝐿 ∗ 𝑊  ].  
Notable increases in 𝑉  were rapidly observed within 1 week of treatment. A 
large decrease in total tumor volume was observed 2 weeks after the start of 
therapy. The study was concluded on day 37 when notable ulceration of the tumors 
was observed. The ANXA5-CBDCA conjugate significantly reduced tumor 




Figure 70: Conjugate dependent tumor growth suppression. The growth of late 
stage 4T1 metastatic breast cancer was monitored in mice (n=5) for a period of 2 
weeks.  Female balb/cj mice of 8 weeks of age were inoculated with an orthotopic 
injection of 105 4T1 cells in the IV mammary fat pad. After a period of 23 days 
mice were treated daily with 5 μg of carboplatin or carboplatin - protein conjugate. 
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Mouse tumor volumes were recorded twice a week and mouse tumor volume was 
determined by the formula [V_tumor-V_Necrosis=(1/3*L*W^2 )_tumor-
(1/3*L*W^2 )_necrosis  ].  
 
Conclusion    
The novel cytocidal bioconjugate ANXA5-CMDCA comprised of the 
protein ANXA5 linked to the chemotherapeutic CBDCA by EDC/NHS chemistry 
is a potent anticancer chemotherapeutic. We establish the degree of CDBCA 
loading on ANXA5 by absorbance spectroscopy, and confirm the anticancer 
activity of the resulting conjugate in a ID8 ovarian cancer model. We further 
demonstrate the activity of the conjugate in vivo using the 4T1 model of late stage 
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Appendix A: Antimalarial Supplemental Data 
 
Protocols 
Candle Jar Method 
The Candle Jar Method described by Jensen et al in 1977 is the first method of 
culturing malaria parasites in vitro  [95]. Malaria parasites are sensitive to 
atmospheric concentrations of oxygen. This method of culturing parasites takes 
advantage of several common pieces of laboratory equipment to create a suitable 
atmosphere for the culture of the parasites. In an airtight chamber, typically a 
candlejar, a sample of blood infected with malaria is placed along with a candle. 
The candle is lit, and the airtight jar sealed. The candle will deplete the oxygen in 
the jar and extinguish. The oxygen depleted atmosphere within the jar is suitable 
for the culture of parasites.  
Mouse Model 
Adult mice of an age ranging between 6 to 8 weeks old, will be inoculated 
with P. berghei ANKA parasites. They will be inoculated either intravenously (i.v.) 
via a lateral tail vein with 105 parasitized erythrocytes (pRBC), or alternatively 




   183 
 
 
erythrocytes out of all erythrocytes (% parasitemia) will rise over the next several 
weeks. As parasite numbers increase the mice will begin to become ill. At 
approximately 5 days post infection (p.i.) mice will begin to exhibit minor 
symptoms of infection including lethargy, ruffled fur and hunching. Within 48 
hours after the initial display of symptoms, mice will begin to display more severe 
neurological symptoms such as convulsions, limb paralysis and coma. Mice that 
survive the 6 to 10 day window of severe neurological symptoms will die ~20 days 
p.i. from hyperparasitemia and anemia.  
 
Infection of C57BL/6J with PbA 
1. PbA stabilate (approximately 0.2–0.5 mL with 1–5 % parasitemia, when 
frozen down) will be kept in liquid nitrogen until required. This 
preparation will contain pRBC in a glycerol-rich (15 % v/v) buffered, 
serum-free medium.  
2. Immediately prior to inculcation the vial of PbA stabilate will be 
defrosted. 
3. Stabilate will be loaded into a 1 mL syringe capped with a 26 or 27G 
needle. Stabilate volume will not exceeding 200 μL and will contain 105 
to 106 pRBC. The stabilate will be injected intraperitoneally into a 6-8 
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4. Mice will then be monitored daily as per the “Monitoring Infected 
Mice” section of the animal models of disease manual[101].   
 
Determination of Peripheral Blood parasitemia 
1. Using a sterile scalpel, <1 mm of the tail will be removed.  
2. Gently running both thumb, and index finger along the left and right 
lateral vein of the tail will milk a small drop of blood from the mouse.  
3. Parasites will be enumerated via blood smear or flow cytometry. 
A) In the case of blood smear, a single drop of blood will be collected 
on a glass slide, dried and then sterilized and fixed in methanol for 
2 minutes. The slide will then be stained with giemsa and parasites 
will be counted via light microscopy. 
B) In the case of flow cytometry, a single drop of blood will be 
collected into a polystyrene microcentrifuge tube. Blood cells will 
be isolated by centrifugication, and then sterilized and fixed in 4% 
paraformaldehyde for 10 minutes. Fixed cells will then be 
enumerated by flow cytometry 
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1. Mice will be visually assessed twice daily starting 5 p.i. , or when 
parasitemia exceeds 4%. 
2. Mice will be assigned clinical scores corresponding the severity of their 
symptoms.  
A) Each of the following symptoms is assigned a score of 1: ruffled fur, 
hunching, wobbly gait, limb paralysis, convulsions, and coma.  
B) When the cumulative score equals or exceeds 4, the animal shall be 
euthanized by C02 asphyxiation, followed by cervical dislocation. 
Following euthanasia records shall be updated to show a score of ‘5’ 
indicating euthanasia.  
 
Preparation of pRBC Aliquots for future Inoculation  
1. Infected mice of 1-4% parasitemia will be euthanized by C02 
asphyxiation followed by cervical dislocation.  
2. Infected blood will be collected by cardiac puncture in a tuberculin 
syringe.  
3. Blood will be diluted in cell growth media, enumerated, and aliquoted 
for either immediate use or for cryopreservation.  
A) Blood for immediate use will be inoculated into mice as per the 




   186 
 
 
B) Blood to be preserved via cryopreservation will be aliquoted into 
glycerol rich media and frozen under liquid N2 
 
Euthanasia Criteria  
1. Mice will be euthanized when their cumulative symptom score equals 
or exceeds 4 (See recommended euthanasia guide IACUC). 
2. Mice will be euthanized if they lose greater than 10% of their study start 
weight.  
3. Mice will be euthanized regardless of cumulative symptom score if they 
display convulsions, and or coma.  
4. Mice will be euthanized if in any way demonstrate obvious pain or stress 









Production of Annexin 
Protein Expression & Purification of AV 
 Day before starting, autoclave the following items:    
 1 liter LB medium  
 4 1 liter Erlenmeyer flask (with aluminum foil on top) 
 125 ml Erlenmeyer flask (with aluminum foil on top) 
 100 ml beaker (with aluminum foil on top)           
 All size tips 
 1.5 ml centrifuge tubes (like 100) 
 1 liter DI water 
 
Protein Expression 
Day 1: 2100 
1. Culture 5 µlof E. coliBL21(DE3) harboring pET303CT with the fusion gene 
AV in10 ml of LB medium containing 35 mg/ml kanamycin in a 125 ml 
Erlenmeyer flask overnight at 37oC with shaking at 200 rpm. 
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 Add 35 mg kanamycin to the 1 L of LB medium before taking out the 10 
ml for the initial culture. 
 Incubate overnight. 
 
Day 2: 900 
2. Add 10 ml of the cell culture to 1 liter of fresh culture medium+ kanamycin 
and incubate at 37oC with shaking (200 rpm). Take 1.5 mL of medium 
before adding the bacteria, as a blank. This cell culture was grown to mid-
log phase => OD600 = 0.5.  
 Transfer 10 mL of bacteria to 1 L LB medium. 
 Transfer entire volume of medium to four 1 L flasks.  
 Put in shaker at 37o C at 200 rpm. 
 After 1.5 h of shaking, measure optical density at 600 nm (absorbance).  
When OD600nm = 0.5 (between .5 and .8 is good), then proceed to next 
step. 
 
Day 2: 1445 
3. Addisopropyl -D-thiogalactopyranoside (IPTG - stored @ -20ºC top 
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flask)to solutions in four 1 L flasksand incubate at 30oC with shaking (180 
rpm) for 5 h to induce protein expression.  
 Take 750 ml sample of solution before adding IPTG.  Label it ‘BI.’  
 Add 24 mg IPTG to each flask. 
 Put back in shaker at 30oC for 5 hours.   
- IPTG stimulates the production of fusion protein.  (IPTG activates the 
promoter in the plasmid that will start the transcription of the gene that follows the 
promoter =>Annexin A5 gene.)  
 
Day 2: 1945 
4. Harvest the cells by centrifugation for 10 min at 1000 x g, at 4ºC.  
 Take 750 ml sample before centrifuge.  Label sample ‘BC.’ 
 Centrifuge at 1000xg = ~3000 rpm (centrifuge uses rpm – consult 
table on machine).  Only 4 – 50 ml centrifuge tubes at a time, temp 
4ºC, 10 mins. 
 After first centrifuge, pour out supernatant, add more culture to same 
4 tubes.  Bacteria will be stuck to side of tubes so inverting to pour 
out is not a problem. 
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Day 3 1000 
5. Resuspendthe cell pellet in 40 ml of sonication buffer.  
 Add ~10 ml to each of the 4 centrifuge tubes. 
 Vortex to resuspend cell pellets. 
 Pour contents of the 4 tubes back into the 100 ml beaker. 
 Sonication Buffer Recipe 
o TPC -0.704 mg. 
o PMSF -6.968 mg. 
o HPLC EtOH - 400 µl. 
o β-mercaptoethanol - 4 µl. 
o sodium phosphate dibasic – 113.6 mg. 
o 40 mL DI H2O 
o Dissolve TPC and PMSF in EtOH 
o Mix remaining ingredients in a beaker 
o Correct solution to pH 7.4 – using HCl 
6. Lyse the cells by sonication on ice for 30 sec at 5 watts then allow it to cool 
for 30 sec on ice. Repeat this cycle 4 more times. 
7. Centrifuge the lysate obtained at 12,000 x g for 30 min to remove the cell 









Day 3: 1200 
8. Add to lysed cells: 
 imidazole - 0.0817 g 
 NaCl - 1.168 g 
9. Equilibrate a 5 ml HisTrap chromatography column with Wash Buffer 1. 
 WASH BUFFER 1 Recipe 
o 500 mL of diH2O 
o sodium phosphate dibasic - 1.42 g 
o imidazole - 1.362 g 
o 500 mMNaCl - 14.61 g 
o Correct this to pH 7.4 
10. Feed the soluble protein fraction into the column.   
11. Remove endotoxin with 350 mL of Wash buffer 2 
 WASH BUFFER 2 (300 mL) 
o sodium phosphate dibasic - 0.8517 g 
o imidazole - 0.817 g 
o NaCl - 8.766 g 
o Trition X-114 - 3 ml 
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12. Remove wash buffer 2 with 100 mL of Wash buffer 1. 
 Wash buffer 2 interferes with Bradford reagent 
13. Elute the protein using elution buffer and collect the elution.  
 ELUTION BUFFER (300 mL) 
o sodium phosphate dibasic - 0.8517 g 
o imidazole - 10.212 g 
o NaCl - 8.766 g 
o Correct this to pH 7 
14. Dialyze eluted protein for 3 hours against 2 liters of dialysis buffer  
 DIALYSIS BUFFER  
o 2 L of diH2O 
o sodium phosphate dibasic =>5.678 g 
o Adjust to pH 7.4 
15. Regenerate the Column with 25 mL each of:  
 KCl (14.91 g in 200 mL diH2O) 
 NaOH (8.0 g in 200 mL of diH2O) 
 diH2O 
 HPLC Grade EtOH (1.46 mL EtOH in 23.5 mL diH2O) 
16. Measure the concentration of protein  










Day 4 1000 
18. Equilibrate the HisTrap column with Wash Buffer 1.    
19. Add imidazole (40 mM) and NaCl (500 mM) to the cleaved protein solution  
20. Feed the solution to theHisTrap column.  
 The protein is in the flow through of this stage.  
21. Feed Wash Buffer 1 into column to pull out all cleaved protein before 
proceeding forward. 
22. Elute uncleaved protein with elution buffer.  
23. Dialyze purified protein for 3 hours against 2 liters of dialysis buffer. 
 DIALYSIS 2 BUFFER 
• sodium phosphate dibasic - 5.5678 g 
• NaCl - 11.688 g 
• Adjust to pH 7.4 
24. Regenerate the column as above. 
25. Sterile filter the protein with a 0.22 uM filter  
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28. Perform Bradford concentration, annexin binding, SDS-page size, and mCGL 











Figure 71: Spectroscopic Analysis Blood [109].  
The relative oxidation state of hemoglobin can be determined by comparative 
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Giemsa Stain Protocol 
1) Fix slides in ice cold 100% methanol for ~30” and rinse off in tap water.  
2) Make up a fresh solution of 10% Giemsa stain in distilled water.  
3)  Stain samples for ~30 – 45 minutes, and observe color development to 
determine rate of stain uptake.   
4)  Rinse off slide in tap water and dry thoroughly using bibulous paper to dab. 
Estimation of Parasitemia  
5)  View slide under oil immersion with a 100x objective.  
6)  Estimate parasitemia by counting the number of infected cells. A 10x10 grid 
square in the eyepiece of the microscope facilitates the procedure as an even 
blood smear yields ~100 erythrocytes per 10x10 grid. Thus for example, 8 
infected blood cells in a 10x10 grid is ~8% parasitemia. Several fields (~10) 
should be counted and the average taken to obtain a representative estimate 








Stability of the Fusion Protein 
The enzyme activity of fusion protein (mCGL-ANXA5) was monitored 
over a period of one month. The activity of samples stored at several temperature 
conditions (4, 25 and 37 °C) was ascertained by colormetric assay. Colormetric 
production of α-ketobutrate with 3-Methyl-2-benzo-thiazolinone hydrazone 
hydrochloride hydrate was quantified and compared to controls of fresh enzyme to 
determine activity (%). Stability of the enzyme was found to decrease rapidly under 
all storage conditions, with the exception of flash frozen samples which maintained 
all activity.  
 
Figure 72: Fusion protein enzymatic stability.  
The enzyme activity of fusion protein (mCGL-AV) was monitored over a period 
of one month. The activity of samples stored at several temperature conditions (4, 
25 and 37 °C) was ascertained by colormetric assay. Colormetric detection of α-
ketobutrate with 3-Methyl-2-benzo-thiazolinone hydrazone hydrochloride hydrate 










The activity of the fusion protein (mCGL-ANXA5) is highly dependent on 
the cofactor pyridoxal-3-phosphate (PP3). PP3 or PLP otherwise known as vitamin 
B6, catalyzes the activity rate of the apoenzyme by several order of magnitude. The 
activity of the haloenzyme can also be increased by 100% with excess (28 mM)  
PP3. 
 
Figure 73: Cofactor dependent activity.  
The activity of the fusion protein (mCGL-ANXA5) is dependent on the cofactor 
PP3.Significant changes in activity were observed in samples (n = 3) of mCGL-
ANXA5 incubated with PP3.  
 



































Figure 74: Cofactor dependent cytotoxicity.  
The cytostatic activity of the fusion protein (mCGL-ANXA5) can be increased in 
vitro with supplemental PP3. Ovarian cells were incubated for 48 hours with 3,500 
nM PP3 or 500 nM of fusion protein supplemented with excess PP3.  While PP3 
has no effect on cells by itself, it catalyzes the cystathionine-γ-lyase activity of the 













Figure 75: Increased cysthathionine-γ-lyase substrate can be detected in blood 
from mice inoculated with L1210 leukemia.  
The colorimetric detection of products of mCGL enzyme activity in mice with 













 Prepare 90% (vol/vol) Percoll (200 ml) by mixing 20 ml of 10× PBS with 
180 ml of Percoll. 
 Prepare 65% (vol/vol) Percoll by combining 6.5 ml of 90% Percoll with 2.5 
ml of incomplete culture medium 
 
 Prepare 35% (vol/vol) Percoll by combining 3.5 ml of 90% Percoll with 5.5 
ml of incomplete culture medium.  
 Mix well and sterilize by filtration through a 0.22-µm filter. The sterile 90, 
65 and 35% Percoll solutions are stored at 4 °C for up to 1 year.  
 
Percol Gradient Casting:  
To cast a step Percoll gradient, use a 3-ml plastic pipette to load 35% (vol/vol) 
Percoll on top of 65% (vol/vol) Percoll (2 ml of each concentration). Hold the 
pipette so that the end is against the inner wall of the 15-ml Falcon tube. Slowly 
release the 35% (vol/vol) Percoll on to the 65% (vol/vol) Percoll layer so that a 








Isolation of of Parasitized RBCs 
1) Transfer the parasite culture from the 25-cm2 flask to a 15-ml disposable 
Falcon tube. Centrifuge at 2,000 r.p.m. (~500g) for 5 min at room 
temperature. Discard the supernatant. Resuspend the cells with 
incomplete culture medium to 10% hematocrit (total ~2.5 ml). 
2) Slowly layer cell suspension on top of the freshly prepared Percoll 
gradient 
3) Centrifuge in a swing-out rotor at 1,500g at room temperature for 15 
min, without braking 
4) Recover parasites from the 35/65% Percoll interface and transfer it to a 
15-ml disposable Falcon tube. 
5) Add 10 volumes of incomplete culture medium drop by drop to the 
recovered parasites, gently shaking after each addition. 
6) Centrifuge cells at 2,000 r.p.m. (~500g) for 5 min at room temperature 
and discard the supernatant. 
7) Wash once more with 10 volumes of incomplete culture medium by 
centrifugation at 2,000 r.p.m. (~500g) for 5 min at room temperature 
and remove the supernatant. 








Culture Conditions of Isolated Parasites 
 5% hematocrit and < 5 % parasitemia  
 RPMI Media with 10 % FBS and no antibiotics 
 25 mm2 petri dishes 
 O2 depleted candlejar 










Appendix B: Chlorambucil-Annexin Conjugate  
Cytotoxicity Assay 
MTT Cytotoxicity Assay (P388 or L1210 Cell Lines)  
 
MTT is a yellow tetrazolium dye that turns purple when it is reduced to an insoluble 
formazan. This reduction is carried out by oxidoreductase enzymes that are 
dependent on NADH or NADPH inside cells. The level of active oxidoreductase 
enzymes is reflective of the cellular metabolic activity. Assays of cellular metabolic 
activity can be used to assay cell health. After solubilizing the formazan produced 
from a cell, the absorbance can be measured and compared to the absorbance of 
formazan in a control solution to determine if cellular metabolic activity has 
increased or decreased. The MTT assay is influenced by the growth phase of the 
cells and variation of metabolic activity amongst different cell types. Cell count 
should be taken during log phase. This protocol is for use with 24 or 96-well plates. 
Protocol 
1) Harvest 5 million cells from culture and dilute to a total of 25 mL with 
media. 








3) Allow cells to rest for at least 1-2 hours. 
4) Treat groups according to experimental protocol.  
5) In this experiment you will add 100 uL of the Chlorambucil-DMSO per well 
6) Incubate cells with chosen treatment for 20 hours.  
7) Add 100 uL of MTT solution to each well  
8) Incubate cells with MTT for 2-4 hours to allow dye uptake. 
9) Transfer contents each well to a microcentrifuge tube.  
10) Centrifuge cells at 1000 RCF (not RPM) for 5 minutes 
11) Discard supernatant in sink by gently flicking vials  
12) Add 1 mL of DMSO to each vial lysing cells and solubilizing the MTT. 
13) Transfer 100 uL of solution from each well to a clear 96 well plate.  
14) Read the absorbance immediately at 540nm.  
 
Supplies 
• 5 million cells 
• DMEM with 10% horse Serum and 1 % Anti/Anti 
• DMSO 
• MTT Stock Solution (62.5 mg of MTT:25 mL of PBS)  
• 24 well plate  








Synthesis of ANXA5-CMB 
1) Dissolve 100 µg of chlorambucil in 50 µL of 12 M HCL(Chlorambucil is 
insoluble at neutral pH, but dissolves readily at pHs below 5. However, 
chlorambucil is unstable in acidic solutions and should not be stored for long 
periods of time in acidic solutions.) 
2) Dilute the mixture in 1 mL of phosphate buffer(This provides a larger 
working volume of chlorambucil to continue downstream production.)  
3) Add 10 mg of EDC(The EDC will bind the carboxylic groups of 
chlorambucil increasing their chemical reactivity towards primary amines.) 
4) Add 7 mg of suflo-NHS (Sulfo-NHS stabilizes the EDC activated carboxylic 
groups, increasing the efficiency of the chlorambucil-annexin reaction.) 
5) Stir vigorously for 15 minutes 
6) Add 2 µL of β-mercaptoethanol (Β-mercaptoethanol neutralizes the excess 
EDC and NHS preventing their interference in downstream reactions.) 
7) Immediately titrate the solution to a pH of 7.4 (Raising the pH stabilizes the 
sensitive chlorambucil functional groups.)  
8) Add 2.33 mL of a 1 mg/ml solution of annexin in phosphate buffer (The 
annexin is kept at a low concentration to prevent precipitation and crosslinking. 







9) Stir gently for 12 hours 
10) Centrifuge for 10 minutes at 7,000 rcf(Chlorambucil is not stable in neutral 
pH solutions and will precipitate. The precipitate is easily removed by 
centrifugation.  
11) Retain the supernatant and discard the pellet 
12) Dialyze the supernatant against 2 L of phosphate buffered saline for 8 hours. 
(This step removes the rest of the unbound chlorambucil as well as other upstream 
contaminants such as β-mercaptoethanol.)  
13) Filter the dialysate using a 0.2 µm filter 
14) Immediately flash freeze under liquid nitrogen and store at -80 °C until 
















Figure 76: Chlorambucil absorbance.  
Chlorambucil has strong absorbance at UV wavelengths. Pictured above are the 
spectra for serial dilutions of chlorambucil. ([Chlorambucil]starting = 10 mg/ml; 











Figure 77: Absorption spectroscopic detection of CHMB. 
Despite strong absorbance peaks in the UV range, an unknown concentration of 
chlorambucil can not be determined with absorbance spectroscopy in samples 
containing protein. When chlorambucil is in the presence of protein the absorption 
spectra of the chlorambucil – protein conjugate is dominated by that of the 
aromatic amino acids of the protein (λ:280). 



























Appendix C: Photothermal Therapy Combined with Checkpoint 
Inhibition 
Tumor Treatment Timelines 
 
Figure 78: EMT6 breast cancer model timeline. 
 
 
Figure 79: B16F10 Melanoma model timeline. 
Day 16 Day 17 Day 18 Day 19Day 15Day 12Day 8Day 1 Day 2 Day 3 Day 13 Day 14Day 9 Day 10 Day 11
Day 1: 
i.v. induct ion of 
pulmonary 
metastasis



























Figure 80: The quantification of SWCNT during the synthesis of SWCNT-
ANXA5.  
We observed that additional sonication resulted in unbundling of SWCNT 
aggregates in solutions increasing absorbance. A modified procedure resulted in 
an updated SWCNT standard.  


























B16F10 Tumor Model 
 
Figure 81: In Vivo detection of B16F10 tumor metastasis by luciferase assay 
following i.v. induction of lung metastasis in C57 mice (n = 3). 
 



























Figure 82: Balb/cj mouse bearing a B16F10 tumor 16 days following a s.c. 
inoculation. 
 
Survey of Immunostimulants in B16F10 
We investigated the interaction between photothermal therapy and tumor 
metastasis. Using fluorescent B16F10-luceferase we artificially induced lung 
metastases by i.v. inoculation with 106 tumor cells. The growth of lung metastases 







Figure 83: The metastatic B16F10-lucerferase lung tumor burden of mice was 
measured with 2D optical tomography imaging. 
 
We monitored lung tumor burden and survival in mice in mice (n = 5) 
following SWCNT-ANXA5 targeted photothermal ablation.  Surprisingly, we 
observed no increase in survival when mice received photothermal ablation or anti-








Figure 84: Survival of B16F10 tumor bearing mice. 
 
Examination of the lung tumor burden of select groups by 2D optical tomography 
imaging 3 weeks following the induction of pulmonary metastasis revealed that 
both photothermal therapy and anti-CTLA-4 blockade increased relative lung 







Figure 85: The relative tumor burden of mice bearing B16F10 metastatic lung 
tumors was determined by 2D optical tomography imaging. Data is presented as 
the mean ± SE (n = 5). 
 
Further efforts employing alternative immunostimulants such as 
cyclophosphamide, anti-PD-1, or anti-CD-73 failed to substantially inhibit tumor 
growth as assayed by mouse weight, fluorescent lung tumor burden or survival 
(Figure 86, 87, and 88). We hypothesize that the rapid onset of mortality in the 




























































Figure 86: Mouse weight Data is presented as the mean ± SE (n = 7). 
 
 
Figure 87: Survival of B16F10 tumor bearing mice. Data is presented as the 
mean ± SE (n = 7). 
 
















































Figure 88: Lung tumor burden. Data is presented as the mean ± SE (n = 7). 
 
Biodistribution Calculation 
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Conjugation of DSPE-PEG-Maleimide linker to Annexin A5 Protein 
Purpose: Use DSPE-PEG-Maleimide linker to functionalize SWCNTs with 
Annexin V protein 
1. Prepare 1% SDS solution. 
a. Prepare 1% SDS stock. 
i. .5g SDS in 50mL DI water. 
2. Prepare SWCNT suspensions.(2 hours and 45 minutesstore in the fridge) 
a. Sonicate the SWCNT solution for 30 minutes. (6mg SWCNT in 5 ml 
1% SDS) 
a. Use SG65i from 5/13/2013. 








































b. Make solution in a glass vial. 
c. Sonicate a maximum. (difficulty turning on/make sure probe 
does not touch the glass vial) 
d. Place vial in water bath to prevent it from overheating. 
b. Centrifuge the SWCNT solution for 30min at 13000rpm. 
a. Store supernatant. 
b. Aggregates will drop to the bottom of solution. 
c. Transfer SWCNTs supernatant solution to new tube and repeat steps a 
and b. 
3. Dissolve DSPE-PEG-Maleimide linker (MW 4368 Da) at 1.5 mg/ml in 1% 
SDS. 
a. Dissolve 1.5mg of linker in 1mL 1% SDS. 
b. Store linker at -20˚C under nitrogen. 
4. Add 1 ml of linker to 5 ml of SWCNT suspension. 
5. Mix at RT for 30 min with gentle shaking on shaker with stir bar. 
6. Dialyze SWCNT-linker for 8 hr against 2 L of DI water. Change the 
dialysate after 4 hr. Use a 2 kD dialysis membrane. 
a. Use green dialysis clips. 
7. Reconstitute 5 mg of annexin a protein with 1 ml of DI water. 
a. Conduct a Bradford Assay to confirm protein concentration. 
i. Mix 5uL of protein and 250uL of Bradford reagent in 96-
well plate with clear bottom. Run blank well with DI water. 
(use aliquot) 
ii. Shake for 30 seconds and incubate at room temperature for 
10 minutes. 
iii. Read absorbance at 595nm. Absorbance should be between 
0.3-1. 
iv. Use standard curve equation to determine concentration. 
8. Take 2 ml of SWCNT-linker suspension and add 5mg of annexin A5 to it. 
(annexin:linker molar ratio= 1.05:1) 
9. Mix the SWCNT-linker and annexin A5 at RT for 2 hr with gentle shaking 
on shaker (3 ml total volume). 
10. Block unreacted linker sites with 0.166 mg of L-cysteine and mix at RT for 
1 hr with gentle shaking. (The molar ration of L-cys:linker is 4:1) For ease, 






11. Dialyze the SWCNT-annexin A5 conjugate for 8 hr against 2 L of 20 mM 
sodium phosphate buffer at pH 7.4 (5.678 g of sodium phosphate/2L DI 
water). Change the dialysate after 4 hr. Use a 100kD dialysis membrane. Do 
not allow this dialysis to go to long—change the dialysate at 3:45 and 
remove from dialysis at 7:30. 
12. Centrifuge the resulting SWCNT-annexin A5 conjugate at 15,680g for 1 hr 
to remove aggregates. 
a. Keep supernatant. 
13. Measure the SWCNT and protein concentrations. 
a. Run Bradford assay for protein concentration. 
b. Measure SWCNT absorbance at 800nm of spec. 
14. Store conjugate at 4˚C. 
 
Flow Cytometry Staining  
Tissue Collection:  
1. Euthanize animal with CO2 inhalation.  
2. Collect blood and place in heparin tube. Spin tube to separate plasma from blood 
and store at -20°C.  
3. Collect lymph node and spleen and place in 5 ml of cold RPMI-1640 medium. 
Place samples on ice and transport to Norman.  
4. Collect remaining tissue (liver, kidney, heart, lungs, intestine, and tumor) place 







Flow Cytomery Buffer Preparation:  
1. Flow Cytometry Staining Buffer (SB): 1X PBS + 0.5% BSA + 0.05% Sodium 
Azide.  
2. Foxp3 Fixation/Permeabilization working solution: Dilute the 
Fixation/Permeabilization Concentrate (1 part) with Fixation/Permeabilization  
Diluent (3 parts). You will need 1 mL of the Fixation/Permeabilization working  
solution for each sample, if staining in tubes.  
3. Permeabilization Buffer: Dilute the 10X concentrate with distilled water prior to 
use. All following procedures with cells should be conducted on ice.  
 
Flow Cytometry Sample Preparation:  
1. Tease apart tissue (lymph node and spleen) into a single-cell suspension by 
pressing with the plunger of a 3-mL syringe with 1 ml of SB into a petri dish.  
Wash plunger 2X with 1 ml SB each time.  
2. Place a cell strainer on top of a 50-ml conical tube. Pass cells from the petri 
culture dish through the cell strainer to eliminate clumps and debris. Wash petri  
dish and stainer 2X with 1 ml SB each time.  







4. Resuspend the cell pellet in a 1 ml volume of SB and perform a cell count and 
viability analysis. a. Add 10 μl of typan blue + 10 μl of diluted cell suspension 
(1:100 dilution) and count live and total cells.  
5. Centrifuge cells as in Step 3 and resuspend in appropriate volume of SB so that 
the final cell concentration is 1 x 107 cells ml-1.  
 
Flow Cytometry Staining  
1. Add 100 μL of cell stock to a 2 mL microvial.  
2. Spin primary antibody tubes to pull solution to bottom of vial.  
3. Stock antibody cocktail  
4. Add stock antibody cocktail (Table 1) and bring final volume to 50 μl with SB. 
5. Incubate for at least 60 minutes at 2-8°C or on ice. Protect from light.  
6. Wash the cells by adding Flow Cytometry Staining Buffer. Use 2 ml tube-1. 
Centrifuge at 400-600g for 5 min at room temperature. Discard supernatant.  
7. Repeat previous wash step.  
8. Add 1 ml of Fixation/Permeabilization working solution to each tube and pulse 
vortex.  
9. Incubate for 60 min at room temperature. Protect samples from light.  
10. Wash the cells by adding 1X Permeabilization Buffer to each tube. Use 1 ml 







11. Repeat previous wash step.  
12. Resuspend pellet in 100 μl of 1X Permeabilization Buffer. This is typically 
the residual volume after decanting.  
13. Block with 2% BSA by adding 2 μl directly to the cells.  
14. Incubate for 15 min at room temperature. 
 15. Without washing, add either 2.5 μL of PE-Foxp3 antibody or SB (Table 1) to 
cells.  
16. Incubate for at least 30 minutes at room temperature. Protect samples from 
light.  
17. Wash the cells by adding 1X Permeabilization Buffer to each tube. Use 1 ml 
tube-1. Centrifuge at 400-600g for 5 min at room temperature. Discard  
supernatant.  
18. Repeat previous wash step.  
19. Resuspend cells in an appropriate volume of Flow Cytometry Staining Buffer. 








Flow Cytometry Repeat Study 
 
Figure 89: Repeat Flow Cytometry Experiments. Data is presented as the mean ± 














































































































































































































































Figure 90: Repeat flow cytometry experiments. Data is presented as the mean ± 













































































































































































































































Appendix D: Characterization of SWCNTs 
Fluorescent Spectroscopy 
 
Figure 91: The emission spectra of SG65i at 532 nm showing the chiral specific 











Figure 92: The emission spectra of SG65i at 638 nm showing the chiral specific 












Figure 93: The emission spectra of SG65i at 671 nm showing the chiral specific 







Figure 94: The emission spectra of SG65i at 785 nm showing the chiral specific 


















Figure 96: SWCNT fluorescent standards of samples measured at different 
excitation frequencies. All sample fluorescent measurements correspond to 
SWCNT 6,5 chirality emission with the exception of 671 and 638 nm which 











Figure 97: In non-biological samples the presence of SG65i SWCNT can be 










Figure 98: The fluorescent emission spectra of SG65i SWCNT showing 





















































Figure 101:  The diameter distribution of SG65i SWCNT was determined by 









Figure 102: SWCNT can be detected in biological samples using 
thermogravimetric analysis. Samples of liver (100 mg) doped with SWCNT (10 





on a microtiter plate reader (n = 3) between 230-260 was measured (Figure 
60). 
 
Figure 103: Carboplatin Absorbance. The absorbance spectra of carboplatin serial-























































Appendix G: SWCNT-DTX Conjugate Characterization 
 
Detection of DTX from DTX-SWCNT 
 




























Figure 106: Acetonitrile isolation of DTX from DTX-SWCNT. 
 
 
Figure 107: Ethanol isolation of DTX from DTX-ANXA5-SWCNT. 
 









































Figure 108: Methylene chloride extraction of DTX from DTX-SWCNT. 
 
 






















The use of phosphate buffer as an antisolvent (new synthesis) significantly 
increased DTX: SWCNT loading compared to the use of only EtOH (original 
synthesis) (Figure 111).  
 
 
Figure 111: Increased DTX loading observed following methylene chloride 
extraction of an antisolvent precipitation synthesis. In the original synthesis 
SWCNTs and DTX were suspended in solution and mixed to encourage 
association. In the new synthesis, phosphate buffered saline was dropwise added to 
a suspension of DTX and SWCNT initiating the precipitation of DTX.   
The amount of DTX within the SWCNT-DTX conjugate can be quantified 
using absorbance spectroscopy. Unknown DTX concentrations were determined in 
the organic phase of a methylene chloride extraction from aqueous standards. 
Standards were  generated by measuring the max absorbance between 200-200 nm 
and plotting this versus docetaxel concentration (Figure 112).  



























Figure 112: Absorbance standard following methylene chloride extraction. 
 
The degree of DTX loading within the DTX-SWCNT conjugate can be 
precisely controlled. A methylene chloride extraction of SWCNT-DTX conjugate 
prepared using different starting concentrations of DTX demonstrates the 
increasing loading of DTX (Figure 113).  































Figure 113: Increasing DTX loading on SWCNT. The absorbance spectra of 
docetaxel following methylene chloride extractions was assayed after the 
synthesis of SWCNT-DTX with 2-fold decreasing initial concentrations of DTX.  
[DTX]starting: 4 mg/mL)  
Appendix H: Antibacterial Assay 
Intracellular Infection 
1) Cells will be incubated with NTHi for 2 hours. 
 10 μL of 1-5 x 109 cfu/ml ( OD@600 nm=0.65 )  
 This should yield 2 x 105 cfu per well, or about 0.1% uptake 
2) Cells will be washed 3 times in PBS to remove excess NTHi 







4) Select samples shall receive excess ANXA5-mCGL (120 nM) and be 
incubated for 3 h.  
5) Wash all wells 3x in dPBS to remove excess ANXA5-mCGL. 
6) Mammalian cells will be passaged by trypsin, and whole cells will be 
lysed by briefly sonicating sample with glass beads. 
7) Samples will then be serially diluted in BHI and plated on chocolate agar 
plates.  







Antibacterial Activity ANXA5-mCGL 
Elaborating on previous work targeting intracellular pathogens (Chapter 1: 
Antimalrial Fusion Protein) the antibacterial activity of fusion protein (ANXA5-
mCGL) was ascertained in an in vitro model of intracellular infection. Mouse 
derived mesenchymal stem cells were seeded into a 96-well microtiter plate at a 
density of 5 x 105 cell per well and allowed to rest for 24 hours. Cell samples were 
then inoculated with 106 CFU of pathogenic Haemophilus influenzae. Intracellular 
uptake of bacteria was encouraged by centrifuging samples at 1000 g for 10 minutes 
at 4 °C. Excess extracellular bacteria were removed by thorough washing with 
HBSS. Samples were then incubated with 75 μg/mL of cell impermeable 
gentamicin for 3 hours to destroy any remaining extracellular bacteria. The 
resulting bacterially infected cells were then used as a model of intracellular 
infection.  
The antibacterial activity of ANXA5-mCGL was then assayed in this 
model. Cultures were treated with 500 μM of fusion protein or a saline control for 
36 hours in antibiotic free medium. After treatment, cells were harvested using 0.25 
% trypsin-EDTA and lysed to release bacteria. Bacteria were then plated on 
chocolate agar plates (Figure 114). Cultures of untreated samples (top, left) were 
almost immediately overgrown. Treated samples (top, right) plated fewer colonies. 







treated with ANXA5-mCGL has significantly fewer viable NTHi colonies (n ≤ 
0.05). 
 
Figure 114: Antibacterial activity of ANXA5-mCGL. Infected cultures of 
mamillian cells treated with fusion protein plated fewer colonies of bacteria then 
controls. Data is presented as the mean ± SE (n = 3)  
